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ABSTRACT 
 
EXPANDING PEPTIDE STAPLING WITH s-TETRAZINE 
Matthew H. Bunner 
Professor Amos B. Smith, III 
 This dissertation presents efforts toward the extension of synthetic methods for 
the creation of peptide macrocycles via the addition of dichloro-s-tetrazine to peptide 
sequences containing lysine, serine, threonine, and tyrosine. Chapter one reviews the 
work and interest of the Smith group in the s-tetrazine chromophore and the history of 
stapled peptides in the chemical literature. Chapter two describes (A) the development of 
a synthetic protocol for the creation of peptide macrocycles from peptide sequences 
containing a single cysteine and a single lysine residue using dichloro-s-tetrazine 
including discussion on amino acid tolerance and seven successful examples, (B) efforts 
toward the development of a synthetic protocol for the creation of peptide macrocycles 
from peptide sequences containing a single cysteine residue and a single serine / 
threonine / tyrosine residue, and (C) efforts toward the investigation of the photochemical 
dissociation of the created cysteine / lysine peptide macrocycles. Chapter three describes 
our efforts to improve the synthesis of dichloro-s-tetrazine in a large-scale procedure. 
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CHAPTER 1. Evaluation of s-Tetrazine in Biophysics: Early 
Work 
In 1975, King and Hochstrasser reported that, upon excitation at an appropriate 
wavelength by a tunable dye laser, s-tetrazine would fragment to give two equivalents of  
hydrogen   cyanide  and   one  equivalent  of  nitrogen  gas  (Figure 1.1).1  This discovery  
 
 
was followed by a collaborative effort between King, Hochstrasser, and Smith to 
investigate the reaction pathway of this photodissociation via the synthesis and 
subsequent decomposition of 1,4-s-tetrazine-15N2. Through mass analysis of the products 
of the photolysis, King et al. were able to show that it was highly unlikely a Dewar-
benzene type intermediate  was involved because the required 1,4-bonding pattern would 
yield nitrogen gas molecules registering m/z values of 28 or 30 (Figure 1.2). Instead, the 
m/z value observed was 29, corresponding to exclusively 14N15N molecular nitrogen.2 
  
 
Figure 1.1. Photodissociation of s-tetrazine1 
Figure 1.2. Eliminated 1,4 bonding photodissociation pathway2 
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 Dellinger and other members of this collaboration also reported a method for the 
exclusive photodecomposition of 12C214N4-tetrazine in the presence of s-tetrazine 
molecules containing the natural abundance of 13C and 15N, thereby proving that the 
enrichment of a material via photo-ablation was possible (Figure 1.3).3,4 This constituted 
laser-induced isotope separation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Selective photodissociation of 12C15N-s-tetrazine. Reprinted with 
permission from J. Am. Chem. Soc. 1977, 99(22), 7138-7142. Copyright 1997 
American Chemical Society.4 
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 A wealth of literature appeared over the next few years concerning the reaction 
pathways of different s-tetrazine derivatives and how those pathways changed based on 
irradiation in vapor phase, mixed crystal, or solution phase experiments.5-10 The 
conclusions drawn from these experiments were that the photodissociation pathway of s-
tetrazines is highly dependent on substitution, solvent, photon energy, and light source 
intensity.6,7 One trend that held throughout these investigations was that attaching 
substituents to the parent ring lowered the yield of the photodissociation.7,8 This trend is 
exemplified by 3,6-diphenyl-s-tetrazine,8 in that π-bond delocalization outside of the 
tetrazine core permits the phenyl substituents to serve as “heat fins” for the dissipation of 
vibrational energy (Table 1.1, Entry 1-3). However, Tucker and coworkers were able to 
demonstrate that including sulfur disrupts the vibrational connection to the substituents, 
thereby increasing the efficiency of the photochemical process. Two possible 
explanations exist as to why the change to sulfur increases the yield of the photochemical 
reaction. One is that the sulfur atoms are sufficiently massive to serve as a barrier to 
energy transfer via vibration.11 This effect is referred to as “the heavy atom-effect.”12 The 
other possible explanation is that the switch to sulfur has opened up new photochemical 
pathways that did not exist in the carbon and hydrogen substituted s-tetrazines. There was 
some experimental evidence presented for this, but further work was never carried out.11 
Other work also highlight the huge difference in photochemical properties between s-
tetrazines substituted with heteroatoms.13-15 Not only could 3,6-bis(benzylthio)-s-
tetrazine undergo photolysis at an acceptable yield under irradiation by 355 nm light, but 
the compound would also undergo photolysis upon irradiation with a 410 nm light source 
(Table 1.1, Entry 4). This made the bis(benzylthio)-tetrazine derivative amenable to 
	
	
4	
biological investigation because peptides and proteins do not generally absorb at this 
wavelength. This beneficial effect carried over to an s-tetrazine derivative substituted 
with two cysteine residues (Table 1, Entry 5). Upon irradiation, fragmentation of the 
tetrazine chromophore occurred within a few hundred picoseconds, making this a 
possible molecule for studying folding interactions in proteins.  
Table 1.1. Photochemical dissociation of substituted tetrazines.11 
 
Entry R Yield (Light Source) 
1  ~90% (532 nm) 
2  ~17% (532 nm) 
3  ~1% (532 nm) 
4  
24% (355 nm) 
12% (410 nm) 
5 
 
11% (410 nm) 
 To verify the compatibility of the s-tetrazine chromophore with biological 
systems and peptide synthesis, Tucker and coworkers developed a method to bridge two 
proximal cysteine residues of a growing peptide chain during solid phase peptide 
synthesis via dichloro-s-tetrazine (1) and an orthogonal protection strategy using highly 
acid-labile monomethoxytrityl (Mmt) in place of the trityl groups standard to Fmoc solid 
phase peptide synthesis (Figure 1.4).11 This resulted in the creation of an oxytocin 
H
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5	
analogue with s-tetrazine bridging the disulfide bond, proving that the tetrazine 
chromophore was compatible with both Fmoc solid phase peptide synthesis and with 
cyclic peptides.11 Photolysis rate and yield of this cyclic tetrazine construct was similar to 
the acyclic versions (Table 1.1, Entry 4-5).11  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.4. Synthesis of [1-Cys, 6-Cys]-S,S-Tet-oxytocin11 
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 This method for the creation of s-tetrazine cyclic peptides via incorporation of 
dichloro-s-tetrazine during solid phase synthesis was then further investigated by Abdo 
and coworkers.16 To test the amino acid compatibility of the synthetic protocol, Abdo et 
al. synthesized a series of peptide trimers featuring two cysteine residues in an i, i+2 
arrangement  with  a  variable  central  amino acid (Figure 1.5).16 A variety of reactive or  
 
 
sterically bulky amino acids where included at the variable position (R), with all tested 
residues except arginine being well tolerated.16 Next, using this method, the effect of 
amino acid spacer length (i, i+x) on the photochemical reaction of s-tetrazine was 
evaluated (Table 1.2).16  The original i, i+2 configuration, corresponding to a half turn of  
Table 1.2. Evaluation of spacer length on photocleavage of s-tetrazine16 
 
Entry Cys Relationship Photochemical Yield 
1 (i, i + 2) > 25 % 
2 (i, i + 3) > 15 % 
3 (i, i + 4) ~ 10 % 
 
Figure 1.5. On-resin synthesis of s-tetrazine trimer peptide macrocycles16 
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an α-helix, was found to give the best yield (Table 1.2, Entry 1). Finally, Abdo and 
coworkers demonstrated that, while this on-resin macrocyclization method was not 
amendable to long peptide sequences, these trimer peptide macrocycles could undergo 
further liquid phase peptide couplings, so other peptide fragments could be added to build 
up larger peptide structures of interest (Figure 1.6).16 
 These trimer peptide tetrazine macrocycles were then used as the cores of a tri-
component union strategy to make alanine-rich α-helical peptides with a constrained 
photo-cleavable kink built into the center (Figure 1.7).17 By strategically placing 13C-18O 
labeled carbonyl pairs at different points within the peptide, it was possible to measure 
rotational changes in the peptide backbone using ultrafast 2D-IR spectroscopy.18 Upon 
photochemical cleavage of the tetrazine chromophore, the kinked helix at the center of 
the peptide was released, and progress of the formation of a single new helical turn could 
be followed via the unique IR signal of the enriched carbonyl pair. These measurements 
established that the kink does not propagate through the helix upon release. Rather, a 
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simple rotation about the previously restricted backbone to reestablish a full turn of the 
helix.18 According to Hochstrasser (private communication to Smith) there is currently no 
theory to explain this folding process. 
  
 
 
 
 
 
 
 
 
 
 
 
 
ABocHN C C CO2H
N N
NN
S S
KAKAFYAcHN CO2HA
6
HN
NH
GAKAKAH2N CONHMe
4
AA
NH
213 19
HN Cbz
Cbz
Cbz
Cbz
1) HBTU, DIPEA,
    oxyma, DMF, 2 h
2) TFA / MeCN (1:3), 2 h
3) HBTU, DIPEA,
    oxyma, DFM, 8 h
4) TFA, 24 h
A
2
AHN C C
N N
NN
S S
O
HN
O
KAKAFYAcHN A
6
NH2
NH2
A
2
GAKAKA CONHMe
4
AA
NH2
213 19
NH2
KKAFYAcHN
6
NH2
NH2
A
2
GAKAKA CONHMe
4
A
NH2
213 19
NH2
S,S-Tet-AKAA5*A6*
O
H
N 13C N
H
18O
13C
H
N
18O
N
H
O
S,S-Tet-AKAA11*A12*
S,S-Tet-AKAA17*A18*
NN
N N
SS
AAA
A
B
Figure 1.7. A) Fragment union strategy for the construction of α-helical peptides17 B) 
Placement of 13C-18O labeled carbonyls for 2D-IR experiments18 
	
	
9	
With this background, Brown and Smith devised and reported a method to get 
away from on-resin synthesis and instead to incorporate the s-tetrazine linker into fully 
deprotected peptides in solution. That is, they developed a method for the creation of 
stapled peptides, via the incorporation of dichloro-s-tetrazine between the thiol side- 
 
 
 
 
 
 
 
 
chains of two proximal cysteine residues in unprotected peptides prepared by standard 
Fmoc solid-phase peptide synthesis (SPPS).19 Following purification, these stapled 
peptides could be subjected to steady-state irradiation under UV-A lamps, cleaving the 
tetrazine chromophore and releasing the peptide macrocycle as the dithiocyanate. Unlike 
the early introduction of staples like Grubbs and Verdine (vide infra),20,21 this was the 
first example of a synthetic organic staple that could be successfully removed with little 
perturbation to the parent peptide. These masked thiols could then be freed by exposing 
Figure 1.8. Peptide stapling and unstapling with dichloro-s-tetrazine (1)19 
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the dithiocyanate peptide to a solution of cysteine, removing the nitriles in a fashion 
similar to native-chemical ligation (Figure 1.8).22 Brown was also able to perform an 
inverse electron-demand Diels-Alder reaction between the tetrazine chromophore and a 
fluorescein dye conjugated to bicyclononynol (Figure 1.9).19 This reaction, commonly 
called “tetrazine ligation,” is a bioorthogonal click reaction and the most common use of 
tetrazine in the literature today.23,24  
 
 
 
 
 
 
 
 
 
 The question that remained at this point in the Hochstrasser-Smith collaboration 
was: Are there other nucleophile side chains that might participate in cysteine cyclic 
ligations to expand the utility of this cyclic peptide construct tactic? Before we discuss 
our investigative effort to probe this question, we should provide some discussion on (a) 
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the history of peptide macrocycles, (b) their importance to the chemical community, (c) 
prominent methods for their creation, and (d) where s-tetrazine fits within that history. 
Importance of Peptides as Therapeutics 
Peptides and proteins have long been thought to hold great therapeutic potential 
by the medicinal chemistry community.25 Through the manipulation of their primary 
structure and secondary conformations, it might be possible to unlock new peptide tools 
to probe biological mysteries or treat illnesses. That is, peptides nicely bridge the 
chemical space in between small molecules and large biologics,26 offering the potential 
therapeutics to modulate targets previously considered “undruggable.”25 For example, 
small molecules are typically considered ill-suited to target the shallow activation site and 
large surface area of protein-protein interactions (PPIs).27 Small molecules are also more 
likely to produce side effects because of the accumulation of metabolites in sensitive 
tissues.28 When compared to larger biologics, peptides are often better suited to 
modulating intracellular targets as their smaller size increases their relative ability to 
diffuse across cell membranes.28 From a more practical standpoint, peptides also have a 
much lower manufacturing cost, and much better room-temperature stability, than large 
biological therapeutics.28   
Challenges of Peptides as Therapeutics 
This is not to say that peptides are free of challenges as therapeutic molecules. 
Being made of amino acids, peptides are typically considered poor targets because of 
their pharmacokinetic profile.28 Because many proteolytic enzymes recognize common 
structural motifs in unmodified peptides, they typically have poor in vivo stability against 
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proteases.28 Additionally, the liver and kidneys both rapidly remove circulating peptides 
from the blood, often resulting in biological half-lives in the range of minutes.28 The oral 
availability of peptides is also rather poor due to low absorption by the impermeable 
gastrointestinal epithelium, the activity of peptidases, and the acidic environment of the 
stomach.29 Lastly, peptides tend not to be as conformationally rigid as small molecules.26 
The time peptides spend sampling different local energy minima across conformational 
space is time not spent providing a therapeutic benefit, lowering binding efficiency and 
overall efficacy.  
Early Peptide Macrocycles 
 Nature provided inspiration for a solution to these problems with the discovery of 
antibacterial peptide gramicidin S (Figure 1.10) by Gause and Brazhnikova in 1944.30 
Synge later identified that gramicidin S is a cyclic peptide.31 Used to treat septic gunshot 
wounds in World War II, this therapeutically useful cyclic peptide paved the way for the 
thousands  of  cyclic  peptides  known  today.28  Many of these peptide macrocycles have  
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therapeutic properties, like oxytocin, cyclosporine a, colistin, and somatostatin.32 The 
conformational constraint created by the cyclic configuration of these molecules imparts 
many beneficial properties that are not found in their linear counterpart.33 Cyclic peptides 
are often more potent, resistant to proteolytic degradation, and are better able to penetrate 
cell membranes.32 
 Depending on the functional groups present within a peptide, macrocyclization 
can occur in four ways: head-to-tail, head-to-side chain, side chain-to-tail, or side chain-
to-side chain (Figure 1.11).32 The most common peptide macrocycle found in nature 
involves a head-to-tail cyclization, forming a large lactam ring between the N- and C-
terminus.34 The second most common cyclic peptides are side chain-to-side chain 
macrocycles formed via disulfide bridge between the thiols of two cysteine residues.33,34 
Because both of these structural motifs are common in nature, proteins have evolved to 
specifically target these bonds for degradation. So while these early macrocycles did 
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Figure 1.11. Four possible configurations of peptide macrocycles32 
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exhibit a conformational rigidity that caused them to spend more time in an active form, 
they were still susceptible to the same degradative weaknesses discussed above for their 
linear counterparts. To overcome this, scientists began developing methods of creating 
peptide macrocycles using non-naturally observed bond linkages. 
Synthetic Peptide Macrocycles 
The rational design of bioactive peptide macrocycles ultimately seeks to replicate 
the naturally occurring three-dimensional secondary structures of proteins, such as turns, 
α-helices, and β-sheets (Figure 1.12). The largest class of protein secondary structure, 
and therefore the most commonly featured structural motif in protein-protein interactions   
(PPIs), is the α-helix.35 The most common way of creating stable α-helical peptides is 
through the creation  of  side  chain-to-side  chain  macrocycles,  early  on  referred  to  as 
 
 
 
 
 
 
 
 
Figure 1.12. Protein secondary structure cartoon of Human 
PCNA (PDB - 1AXC) (turns are green, helices are red, sheets are 
yellow) 
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“stapled” peptides, although the term has now come to include all side chain-to-side 
chain peptide macrocycles.36 The first major breakthrough in the creation of stapled 
peptides using non-native bonds was achieved by Blackwell and Grubbs via ring closing 
metathesis using two allylic ether serine residues spaced in an I, i+4 fashion (Figure 
1.13).20 This work was later expanded upon by Verdine and coworkers when they 
introduced an all hydrocarbon staple, investigating stereochemical configuration, α-
substitution, linker length, and residue spacing for the optimal increase in overall helicity 
and  eventual  biological  activity.21 The current state of  all-hydrocarbon  peptide stapling 
 
 
 
 
 
 
 
has been nicely reviewed by Walensky and Bird.38 The successful implementation of a 
synthetic staple resulting in improved biological activity by Verdine and coworkers 
ignited a veritable arms race to develop new methods for the creation of peptide 
macrocycles.  
O O OO
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Figure 1.12. Early all-hydrocarbon peptide stapling 
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Modern Stapled Peptides  
From this beginning, the field of peptide stapling has exploded in the last 20 years 
as more and more techniques emerge. These methods can be divided into two categories: 
one-component and two-component stapling (Figure 1.14).37 One-component stapling is 
an intramolecular strategy that uses side-chain functionality present within the peptide to 
form the macrocycles. Prominent examples from this category include (a) lactam stapling  
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using native lysine and aspartic acid residues originally pioneered by Rosenblatt39 and 
extensively studied by Fairlie,40 (b) the all-hydrocarbon work already discussed by 
Grubbs20 and Verdine,21 (c) thiol-ene click photochemistry as pioneered by Anseth,41 and 
(d) the copper catalyzed azide-alkyne cycloaddition, brought to solid phase peptide 
synthesis by Meldal.42  Two-component stapling on the other hand, comprises an 
intermolecular, bicomponent strategy that joins the side-chains of two amino acids with a 
second component to form a macrocycle by bridging the two residues.43 The chemical 
space of two component staples is incredibly diverse, with great strides made by the 
following series of colleagues: Pentelute,44-49 Pentelute and Buchwald,50-51 Woolley,52-54 
DeGrado and Greenbaum,55 Caddick and Chudasama,56 Wilson,57 Inouye,58 Baran,59 
Derda,60 Rivera,61 and Spring.62-63  These strategies taken together come with unique 
benefits and drawbacks. Many involve the use of poisonous metals, which can be hard to 
remove to a satisfactory level for eventual biological medical application. Others involve 
the use of non-natural amino acids, which increase the cost of production. These stapling 
strategies also do not allow for the cleavage of the peptide macrocycle (i.e., unstapling) 
without significantly damaging the peptide.  
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CHAPTER 2. Expanding Peptide Stapling with Dichloro-s-
Tetrazine 
	
 While the work of Brown and Smith1 nicely validated the use of dichloro-s-
tetrazine  (1) as a peptide stapling and unstapling reagent in peptide sequences containing  
 
 
two free cysteine residues and in turn highlighted the utility of this tactic, the use of two 
cysteine residues can be problematic. Cysteine is one of the least commonly encoded 
proteogenic amino acids.2-3 Hence, every inclusion of a cysteine in a natural amino acid 
sequence is purposeful, but the inclusion of cysteine residues in sequences solely for use 
of the stapling tactic can add unnecessary difficulty. For example, cysteine makes an 
excellent nucleophilic scavenger,2 and in particular it tends to pick up cationic fragments 
cleaved from other residues in the global deprotection and resin cleavage protocols 
common to Fmoc-SPPS.4 The inclusion of other thiol scavengers in the cleavage cocktail 
can of course help minimalize this byproduct formation, but as the intramolecular cation 
transfer from another residue to cysteine proceeds faster than an intermolecular one, 
some amount of undesired adduct is usually isolated. Cysteine is also sensitive to 
oxidation.2-4 Therefore peptides containing free cysteine need to be handled in dilute, 
acidic environments to suppress the formation of disulfides. The free thiol side-chains of 
cysteine are also quite hydrophobic, making it necessary to include ion-forming residues 
like arginine or lysine in the sequence to aid solubility. Finally, the presence of cysteine 
N N
NN
Cl Cl
1
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is accompanied by a characteristic odor that many find unpleasant. Although workable, 
more than a few scientists may avoid handling these compounds for that reason. For all 
these reasons, the feasibility of utilizing other nucleophilic side chain-containing amino 
acids, lysine in particular, to form stapled peptides from dichloro-s-tetrazine was 
explored as the subject of this thesis.  
Modification of Cysteine/Lysine Peptides with Dichloro-s-tetrazine 
 This research program was thus initiated by investigating the modification of a 
cys-ala-lys trimer peptide, isolated as the trifluoroacetic acid (TFA) salt (2), with 
dichloro- 
 
 
 
 
 
s-tetrazine (1), expecting to arrive at the acyclic product 3 or the closed macrocycle 4 
(Figure 2.1). Not wanting to repeat history, the first conditions explored involved the 
exact protocol previously developed by Brown and Smith for the creation of tetrazine-
bridged disulfide macrocycles from peptides containing two proximal cysteine residues.1 
Isolation and purification by HPLC and analysis by LCMS showed the isolated material 
to be an approximate 2:1 mixture of the desired para-chloro product 3 to undesired para-
hydroxy product 5.  
 
Figure 2.1. Modification of cya-ala-lys trimer peptide with dichloro-s-tetrazine 
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Attempts at further purification of the isolated mixture resulted in the almost 
complete loss of 3, with a small amount of closed macrocycle 4 detectable in the 
chromatogram along with the major product 5. One might think that this still provides a 
path forward, as alcohols can be converted to any number of electron-withdrawing 
leaving groups that are useful in the SNAr reaction manifold, but this fails to take into 
account the extremely electron deficient character of tetrazines and their potential to 
undergo cyclo-elimination. If one were to draw the resonance contributor of 5 wherein 
one of the lone pairs of the phenolic alcohol is delocalized into the s-tetrazine ring, the 
subsequent movement of electrons would result in the dissociation of the s-tetrazine 
moiety, yielding an equivalent of nitrogen gas, isocyanic acid (6), and thiocyanate 
peptide 7 (Figure 2.2). This proposed degradation pathway of 3 to 5 to 7 is supported by 
mass spectrometry evidence. After five minutes, the major component of the reaction 
mixture is still product 3 with little sign of degradation (Figure 2.2C). However, after 
stirring 24 hours, new mass spectrometry analysis (Figure 2.2D) clearly shows that, 
while some compound 3 still remains, the major components of the sample are now 
compounds 5 and 7. The results of this experiment made it abundantly clear that the 
competing reactivity of water while handling any compounds such as 3 would be a 
complicating  factor   not  observed   in   previous   studies   by  Brown.1 Because  of  this  
5
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S
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N
NN
N
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Figure 2.2. A) Proposed degradation pathway of hydroxy-tetrazine; B) Degradation of 3 
to 5 to 7 with molecular weights; C) Formation of compound 3 – mass spectrum of the 
reaction mixture after 5 minutes; D) Formation of comound 3 – mass spectrum of the 
reaction mixture after one day 
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particular difficulty, consideration would have  to  be  paid  not  just  to which reagents  
and conditions were used,  but also to how the material was handled throughout the 
overall reaction process in order to minimize time spent in contact with water. 
 The non-innocence of water posed an interesting/difficult problem. In classic 
organic chemistry, the solution would entail replacement of water with a different 
solvent. Highly polar organic solvents that exhibit no nucleophilic character certainly 
exist, with acetonitrile (MeCN), dimethylsulfoxide (DMSO), and N,N-
dimethylformamide (DMF) often playing a role in reactions requiring these properties. 
However, acetonitrile does not adequately dissolve many of the peptide sequences when 
isolated as salts. As a solid/liquid biphasic reaction mixture would lead to an artificially 
high concentration of the peptide substrate, leading to complications with dimerization, 
acetonitrile was ruled out as a possible solvent.  DMF and DMSO would be better solvent 
choices for peptides, but they are difficult to remove once the reaction is complete due to 
their high boiling point. Again, in classic organic synthesis the product of the reaction can 
often be extracted into a more volatile organic solvent after the reaction mixture has been 
appropriately diluted with water, but the peptide products remain in the aqueous fraction, 
especially if the lysine residue is still present as an ammonium salt. Vacuum distillation 
can also be employed, but removal of the last residual solvent still usually requires 
diluting the mixture with a more volatile co-solvent such as water or methanol and then 
concentrating again several times. Exposing compounds such as 3 to the required 
temperature to achieve vacuum distillation of DMF/DMSO for the length of time 
required for such dilute reactions would also be ill advised from a stability standpoint. 
These solvents can be evaporated by blowing stream of air over the surface of the 
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solution, but the extremely dilute conditions usually used in macrocyclization reactions 
(~1-5 mM) mean that this method of drying would again take a prohibitively long time.5-6 
While DMF and DMSO are regularly employed in peptide modification chemistry, 
workup and purification of protocols utilizing these solvents involves HPLC purification 
to isolate the compound from the solvent.7-9 As discussed above, HPLC purification is 
not an option at this stage. 
 Without a viable alternative, water would have to remain in our reaction protocol. 
Therefore, the first part of reaction optimization for the transformation from 2 to 3 
required a careful evaluation of when water was introduced and what can be done to 
mitigate the degradation undergone by product 3. One way to cut exposure to water 
would be to eliminate HPLC purification and carry the crude material directly forward 
instead of trying to isolate 3 as a pure compound. The first attempt at this strategy 
entailed a two-step protocol skipping any isolation or workup of 3. Instead, dibasic 
sodium phosphate salt would be immediately added after the two-minute stirring period 
to afford an appropriate pH in an attempt to arrive at macrocycle 4 in a one-pot process 
(Figure 2.3). However, instead of desired product 4, LC/MS analysis revealed the major   
product was compound 8. Attempts to ameliorate this issue by using a 1:1 ratio of peptide 
2 to dichloro-s-tetrazine (1) resulted in increased formation of dimer 9 (Figure 2.3). 
Given we were trying to avoid purification, formation of dimer 9 cannot be 
allowed to occur because of the potential to divert other equivalents of 3 away from 
macrocycle formation upon pH change in a polymeric fashion. Therefore, it was 
important  to keep  the equivalents  of dichloro-s-tetrazine (1) sufficiently high to achieve  
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full consumption  of 2 and not  to permit any formation  of dimer 9.  Because changing 
pH to achieve a two-step one-pot macrocyclization under these conditions resulted in 
significant formation of compound 8, as discussed above, this indicates that the isolation 
of compound 3 by lyophilization before performing the macrocyclization step would be 
required (Figure 2.4). Pleasingly, removal of excess dichloro-s-tetrazine (1) was not a 
problem in this reaction sequence given that it is sufficiently volatile to be removed by 
sublimation with the solvent during lyophilization. 
 
 
 
 
 
Figure 2.3. Attempts at two-step, one-pot macrocyclization 
Figure 2.4. Revised plan 
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 The next factor that required improvement was the stability of the crude isolate 
containing intermediate 3. The large excess of sodium phosphate (100 mM buffer vs. 1 
mM peptide) in solution appeared to be leading to inconsistency in lyophilization 
process. That is, the concentration of salt within the flask increases as the water and 
acetonitrile sublimate. This would sometimes result in the ice to thawing, destroying the 
isolated material. Even in reactions that had been successfully dried, there was some 
doubt as to how much water the salt would retain. For example, the crude isolate of 
compound 3 could only be stored in a freezer for a few days before converting to 
compound 5. To ameliorate this issue, various other buffer species were evaluated to see 
if one would give better performance than the phosphate buffer (PBS) currently being 
employed. Criteria for success was a high conversion of 2 to 3, with minimal formation 
of 5, both before and after lyophilization when analyzed by LC/MS. Using the conditions 
described above, a number of buffers including ammonium phosphate, sodium acetate, 
and sodium citrate at 100 mM were evaluated. The reaction was also performed in Milli-
Q water as a control. All buffers performed similarly, showing complete consumption of 
2 and ~95% 3 by LC/MS analysis after stirring for 2 minutes, except for sodium acetate, 
which gave a 2:1:2 mix of compounds 3, 4, and 5. Surprisingly, the reaction run with 
Milli-Q water performed just as well as the successful buffer trials. This observation 
turned out to be a pivotal discovery because, after lyophilization, the only compounds 
present in the flask were 3 and 5. Importantly, this crude isolate of compound 3 could 
now be stored for roughly two weeks without exhibiting significant degradation. 
 As a result of these experiments, suitable conditions were now available for the 
isolation of compound 3 in acceptable purity to carry forward without the need for HPLC 
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purification (Figure 2.5). However, initially there were some difficulties in consistently 
producing  these  results.  Applying  even  greater  levels  of  scrutiny  to  our  attempt   at  
 
 
 
 
 
achieving reproducibility, we found that the inconsistency in the results reflected 
different lengths of time required to completely lyophilize the reaction mixture. That is, 
the longer it took to lyophilize the reaction mixture, the more of the unwanted compound 
5 was produced. To curtail this issue, particular care had to be taken as to how the 
reaction vessel was frozen. There are two ways to freeze a sample to prepare for 
lyophilization, referred to here as “block freezing” and “shell freezing” (Figure 2.6). The 
water/acetonitrile mixture that makes up the solvent for these reactions is readily frozen 
in preparation for lyophilization by submerging the reaction vessel in a dry ice / acetone 
bath. To block freeze a compound, the flask could be placed in a cooling bath and 
allowed to stand until the contents had fully solidified. As shown in Figure 2.6, this 
results in a mass of ice that is not evenly distributed around the edge of the flask. Because 
the rate of evaporation depends on available surface area, this manner of sample 
preparation would often require multiple days to yield dry isolate. If the reaction vessel 
were instead constantly rotated sitting in the bath, the frozen reaction mixture would be 
evenly distributed around  the flask with a much greater surface area, providing access to 
 
Figure 2.5. Conditions for formation of 3 
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dry material in roughly 12 hours. This also set an upper limit on the scale of this reaction. 
As long as the reaction volume was kept under 50% of the total volume of the vessel, 
(e.g.,  50 mL  of a 100 mL  round bottom flask),  the crude material could be recovered in 
12 – 24 hours depending on the current workload on the lyophilizer. If the reaction 
volume was closer to 80% of the total volume or higher, the reaction mixture would not 
have the favorable shell surface area to volume ratio regardless of freezing method and 
would take many days to yield dry material. To this end, a rotary evaporator could be 
employed to rotate the reaction vessel in order to achieve a uniform thickness of frozen 
material without requiring the experimenter to manually turn each flask. This last critical 
observation as to the influence drying time had upon the reaction finally yielded 
consistently reproducible results (>95% conversion of 2 to 3, >80% purity by mass 
spectrometry [Figure 2.7]) that would now permit closure of the macrocycle to be 
investigated.	
	
Figure 2.6. "Block" and "shell" freezing of a 50 mL reaction 
mixture in a 100 mL vessel 
	
	
34	
  
 
 
 
 
 
Macrocyclization of Modified Peptides (3) Possessing a Lysine Side Chain 
 The investigation into conditions to reliably furnish macrocycle 4 was begun by 
testing phosphate and carbonate buffer systems at 0.1 M strength between pH 8 – 11 
(Figure 2.8). Earlier investigations, vida supra, exploring the feasibility of a two-step, 
one-pot procedure for the synthesis of 4,  resulting in the synthesis of bis-tetrazine adduct  
 
 
 
 
 
8 (Figure 2.8), had already indicated that the Nε-amino group of lysine could indeed 
participate as a nucleophile in the PBS buffer system at pH ~ 9. The observance that the 
two-step, one-pot attempt largely resulted in the synthesis of compound 8 also served to 
illustrate that 1 is a more reactive electrophile than 3, as is to be expected from 
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Figure 2.7. Mass spectrum of crude isolate of compound 3 
Figure 2.8. Investigating macrocyclization conditions 
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observance of electronegativity.  This result begs the question of whether or not it will be 
possible to effectively cyclize 3. Once again, the major competing reaction pathway 
would entail solvolysis by water at the para position to form compound 5. It was 
observed during the reaction condition screen that raising the pH of the buffer resulted in 
an increase in the amount of compound 5 present in the mixture. Pleasingly, PBS buffer 
and sodium bicarbonate both gave access to macrocycle 4 at pH ~8.5 after stirring at 
room temperature for two hours. The true difference in usability between the two buffer 
systems became apparent when scaling beyond test reactions and attempting to purify via 
HPLC. As with the reaction to form compound 2, the macrocyclization reaction was run 
under dilute conditions (1 mM of 3, based on the original amount of 2) to impede the 
formation of dimers. Under these conditions 100 equivalents of the buffer species in the 
reaction mixture needed to be removed. On small scale (~5 mg starting peptide), this did 
not create a major problem as the lyophilized crude material could easily be dissolved in 
1 mL of water and the total solute would not overload the capacity of the HPLC column,  
resulting  in  a clean  separation  of  components (Figure 2.9).  However, as  the  reaction 
 
 
 
 
 
was scaled up, it became increasingly difficult to purify the reaction  run with  the sodium  
phosphate buffer  system (Figure 2.10).  The crude isolate had to be diluted far beyond 
what  was necessary  for the peptide material alone before purification to avoid saturating 
Figure 2.9. HPLC purification of macrocycle 4 synthesis on small scale using sodium 
phosphate (left) and sodium bicarbonate (right) 
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the HPLC column with all the salt remaining after lyophilization. Attempts were made to 
ameliorate this issue utilizing dialysis and reverse phase “flash” column chromatography 
as tactics of removing salt prior to HPLC purification, but these procedures added extra 
days of processing time for, at best, modest benefit. Ultimately, neither of these measures 
ameliorated the need for multiple HPLC purifications to arrive at clean material. Working 
with residual carbonate buffer proved much more facile. Samples containing residual 
sodium bicarbonate buffer could be prepared for HPLC purification by dissolving the 
crude isolate in a 1:1 mixture of water and trifluoroacetic acid, allowing much of the salt 
to evolve from solution as carbon dioxide. This tactic avoided the excessive HPLC 
purification that was needed when using 100 mM sodium phosphate buffer, especially as 
the carbonate buffer strength could be lowered to 25 mM with no loss of function. This 
final change permitted the successful synthesis and isolation of pure macrocycle 4 after 
stirring for 2 hours at room temperature in 48% yield over the two steps discussed above 
(Figure 2.11).  
Figure 2.10. HPLC purification of scaled up synthesis of 4 using sodium phosphate. Too 
much salt saturates the column, preventing any retention / purification of material. 
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Figure 2.11. A) Successful conditions for the synthesis of macrocycle 4; B) isolated 
starting peptide 2 as amorphous white powder; C) isolated pure macrocycle 4 as 
amorphous orange powder; D) 1H NMR spectrum of macrocycle 4 in d6-DMSO 
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Scope and Tolerance of Cysteine/Lysine Stapling 
The aim of the next series of experiments was application of this newly developed 
synthetic protocol to other peptide sequences containing a single cysteine and a single 
lysine. The first question was whether the presence of other nucleophilic side chains 
would interfere with S,N-macrocycle formation. To this end, a series of heptamer 
peptides with the cysteine and lysine residues in an i, i+4 relationship, with a variable 
residue in an i+1 relationship relative to cysteine was synthesized (Table 2.1). Using 
phenylalanine (10a) as a control, tyrosine (10b), serine (10c), and arginine (10d) residues 
were interrogated. In every case, conversion of starting peptide 10a-d to acyclic 
intermediate 11a-d could be readily observed via LCMS. However, when attempting to 
form macrocycles 12a-d, unexpected results were encountered! Macrocycle 12a was 
proposed as a control example, but none of the desired product was isolated after 
purification. LC/MS testing at 60 and 120 minutes revealed that desired product 12a 
formed cleanly with little else in the chromatogram, but the HPLC trace and post-
lyophilization LC/MS analysis revealed degradation during the purification process 
(Figure 2.12).  Compound 12b exhibited the same behavior. Pleasingly, peptides 10c and 
10d did provide the desired stapled peptides 12c and 12d in 37% yield and 61% yield 
respectively. Looking at the results displayed in Table 2.1, the determining factor of this 
compound series would appear to be steric bulk rather than chemical reactivity. That is, 
there must be some amount of steric clash in the cys-phe-leu or cys-tyr-leu sequence of 
12a or 12b respectively that causes 12a-b to be less stable than 12c-d.  
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Table 2.1. Competing residue scope 
 
Entry X residue Side chain 
11x LCMS 
Conversion 
12x isolated yield 
(2 steps) 
a Phe  95% 0% 
b Tyr 
 
80% 0% 
c Ser  92% 37% 
d Arg 
 
92% 61% 
Figure 2.12. LC chromatogram data for macrocycle 12a; Top - reaction at 60 
minutes; Bottom - sample post lyophilization 
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 To test this theory, the synthesis of macrocycles 13-16 (Figure 2.13) was 
explored. Pleasingly, all attempts proved successful, providing access to macrocycles 13-
16 in modest to fair yield (20 – 63%) over the two steps! Attempts to construct two larger 
peptide macrocycles (17-18) containing cysteine and lysine residues on opposite ends of 
the peptide chain showed successful construction of the macrocycle by LC/MS, but these 
constructs did not survive attempts at purification. Given the length of these peptide 
chains, steric clashing no longer seems a viable answer as to why these  sequences do not 
 
 
 
 
 
 
 
 
 
 
survive purification. We propose that the adjacent tyrosine residue must exhibit another 
undesirable property other than the steric encumbrance discussed above, such as 
Figure 2.13. More cys-tet-lys macrocycles 
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competing as a nucleophile or somehow rendering the macrocycles more susceptible to 
hydrolysis. The role of tyrosine will be discussed further below.  
The results presented above identify some of the problems that have been 
encountered with this stapling tactic. The S,N-tetrazine linkage appears to have issues 
with instability, with steric encumbrance possibly contributing somewhat to the problem. 
Additionally, these macrocycles are much less soluble than the parent peptides. Not only 
are macrocycles less soluble than their linear peptide counterparts as a general rule, but 
upon cyclization the initially present ammonium group on the lysine side chain is 
replaced with a group that is much less soluble, given how much more difficult it is to 
ionize the nitrogen now attached to the tetrazine ring after macrocyclization. This idea is 
born out by NMR integration evidence, wherein the linear parent chain ammonium 
hydrogen signal integrates for an obvious 3 protons, but the exocyclic nitrogen proton of 
the macrocycle only integrates for 1.  Moreover, the NMR signal of this proton exhibits 
distinct splitting pattern showing that it does not readily exchange, exchangeability being 
a characteristic of acidic protons as exhibited by the ammonium protons in 2 (Figure 
2.14). The good news is that this effect can be mollified by the inclusion of arginine 
residues, which were shown to be tolerated as indicated in Table 2.1 (see example 12d). 
In fact, this proved to the best performing example of that screen! Alternatively, peptide 
19 and acyclic intermediate 20 were completely water soluble, but macrocycle 21 could 
only be dissolved in 2:1 trifluoroacetic acid and tetrafluoroethanol. The loss of aqueous 
solubility in macrocycle 21 was so great that it crashed out inside the steel tubing in the 
HPLC instrument  and further  on the  column during  HPLC purification  and thus could 
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not be purified (Figure 2.15). The stark contrast in solubility and performance between 
12d and 21 serves to highlight how dependent this method is on the peptide substrate. 
 
 
 
 In summary, we set out to translate the previously developed method of creating 
s-tetrazine peptide macrocycles using peptide sequences containing two cysteine residues 
Figure 2.15. Solubility problems with macrocycles  
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to peptide sequences containing a single cysteine and a single lysine. While this 
investigation ultimately resulted in the successful synthesis and purification of seven S,N-
tetrazine macrocycles in yields of 20-63%, it was also made clear during this work that 
the method displayed much less general applicability than that previously developed by 
Brown and Smith.1 In the course of this investigation we encountered problems stemming 
from competing reactivity from solvent, stability of material, and substrate restrictions 
based on steric encumbrance. Our efforts toward circumventing these problems have 
been enumerated and, where possible, solutions have been implemented and tested. 
 The existence of alkyl tetrazine ethers in the literature and the evidence that the 
presence of tyrosine also plays a negative role in the formation of cys-tet-lys macrocycles 
encouraged us to investigate if this method could be employed to create peptide 
macrocycles using cysteine and serine, threonine, or tyrosine as nucleophilic side 
chains.10-19 We therefore explored three peptide sequences (22-24) as initial trial 
candidates for serine and threonine (Figure 2.16). Unfortunately these sequences 
exhibited slightly worse aqueous solubility than the cysteine / lysine counterparts, so we 
had to include PBS buffer (10 mM, pH~5) and change the acetonitrile/buffer ratio from 
1:9 to 1:1. We also raised the equivalents of dichloro-s-tetrazine employed back to 4. 
Intermediates 25-27 could be observed by LC/MS using these conditions. We next 
attempted to close intermediates 25-27 to macrocycles 28-30 using PBS buffer at pH 6-9, 
periodically testing the reaction mixture using LC/MS out to one hour. While a mass hit 
for the desired compounds could occasionally be seen in the MS chromatogram, nothing 
survived  in the  crude isolate  post-lyophilization.  We also tried  heating the reactions  to  
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35°C and saw a small uptick in the amount of macrocycle being formed, but it again did 
not survive purification.  
 We also explored the use of two sequences (31-32) shown in Figure 2.17 to 
investigate the creation of macrocycles with cysteine and tyrosine.19 To synthesize the 
acyclic intermediates 33-34, we could use either the previously discussed method (Figure 
2.16) for peptides containing serine and threonine, or the method previously developed 
for the cysteine/lysine macrocycles. Both gave acceptable results for the cysteine/tyrosine 
peptide substrates. Again we investigated a number of buffers in different pH ranges to 
find conditions to form macrocycles 35-36. Optimal conditions for the formation of 35 
(as observed by LC/MS) were found employing PBS (pH 7.5) over one hour at room 
temperature,  while  36  was  most  reliably  formed  with  ammonium   phosphate  (pH 6) 
Figure 2.16. Attempts at making cys-ser/thr macrocycles with s-tetrazine19 
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(Figure 2.18), also over an hour at room temperature. Unlike the serine/threonine cycles 
discussed above, the correct mass signals were in fact present by LC/MS analysis of the 
material recovered from HPLC purification of 35-36 after lyophilization (Figure 2.19).  
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Figure 2.18. Synthesis of 36 - reaction mixture at 60 minutes 
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However, we found the isolate also retained a small amount of hydrolyzed product. Not 
discouraged by this, the products were again purified by HPLC (Figure 2.20, top). The 
purification chromatogram clearly revealed separation of the minor hydrolysis 
Figure 2.19. HPLC (top) and LC/MS (bottom) data from the first purification of 36 
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contaminant, but 1H NMR analysis of the isolated material indicated the isolated material 
was not a single pure compound (Figure 2.20, bottom). Of particular importance was the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.20. Second HPLC purification of macrocycle 36 (top) and 1H NMR spectrum of 
isolated material (bottom) (~70% pure) 
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small peak at σ = 9.30-9.21, corresponding to the phenolic proton of the tyrosine side 
chain, showing that this sample once again contained acyclic material. A third HPLC 
purification clearly showed removal of the same impurity with the same retention time, 
while  LCMS  analysis  of the  recovered  material  again  showed  that  the  impurity had 
reappeared (Figure 2.21). To verify that the compounds were hydrolyzing in the presence 
of water, macrocycle 36 was stirred in Milli-Q water and the progress of solvolysis was 
monitored by LC/MS. After a 5 days, only 40% of the macrocycle remained.  
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 The results of these investigations reveal that it is simply not feasible to use 
dichloro-s-tetrazine as a reagent for the creation of peptide macrocycles using cysteine 
and serine, threonine, or tyrosine. While alkyl-tetrazine ethers exist in the literature, they 
are largely produced with modest success at best (25% average) and even successful 
examples make use of quite harsh conditions (Figure 2.22).10-11,13 Despite the initial pro- 
 
 
 
 
-mise given by the successful formation of these macrocycles in situ, the aqueous 
sensitivity we observed also seems to be born out by many procedures calling for the use 
of rigorously dry solvent or molecular sieves.10-11 Perhaps this problem could be 
ameliorated if the inverse electron demand Diels-Alder reaction were performed on the 
macrocycle before purification. The staple should then be less susceptible to hydrolysis 
once its electron deficiency is improved, although there would be no way to 
photochemically remove the staple after this modification. Nonetheless, its possible that 
employing this method could result in a stable stapled peptide. 
Cys-Tet-Lys Macrocycles as Photochemical Substrates – Unexpected Difficulties! 
As the foray into the chemistry of s-tetrazines within the Smith group began by 
studying photochemistry,20-23 it would be remiss of us to not conduct some investigation 
into the photochemistry of the S,N-tetrazine macrocycles, although this was an endeavor 
where the collaboration of the late Robin Hochstrasser would be sorely missed! First, an 
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HO OH
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50%
Figure 2.22. Synthesis of small molecule alkyl-tetrazine ethers11 
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assessment of the changes in physical properties moving from S,S- to S,N-tetrazine 
substituted macrocycles had to be undertaken with particular regard to how such changes 
might effect the photochemistry. As discussed in Chapter 1, it has been put forth in the 
literature that bis sulfur substitution of s-tetrazines allowed for photochemical 
decompositions  to occur because  the sulfur atoms  acted as barriers to the  dissipation of  
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Figure 2.23. UV-vis absorption spectra of a S,S-tetrazine (A) and S,N-tetrazine peptide 
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absorbed  energy via  vibrational  relaxation.24-25  It was apparent  that  trading  one of the 
sulfur atoms for nitrogen may increase the photochemical stability of the S,N-tetrazines 
by increasing avenues for the vibrational dissipation of energy. UV-vis spectroscopy 
(Figure 2.23)  also shows that the n – π* and π – π* transitions are much closer in energy      
in the S,N-tetrazine system than in S,S-tetrazines. These two transitions typically 
correspond to the two absorption bands in the 350 – 600 nm region.10-11 While there have 
been several reports of amino-substituted tetrazines, including discussions on their 
fluorescent properties, none have mentioned pursuing photodissociation of these 
compounds.10-11,26-29 
Our first investigation into the photochemistry of stapled macrocycle 4 began 
with the conditions employed by Brown and Smith to achieve unstapling of the S,S-
tetrazine macrocycles.1 That is, a 3 mg sample of pure macrocycle 4 was dissolved in ~10 
mL of methanol and sparged with O2 gas before being irradiated with UV-B lamps (λmax 
= 312 nm) over 17 hours, testing the progress of the reaction by LC/MS taking periodic 
aliquots every 60 minutes (Figure 2.24). There have been conflicting reports in the 
literature about the ability of tetrazine to undergo intersystem crossing and inhabit a 
triplet-excited state.10-11,29-31 Molecular oxygen is included as a sparging gas to quench 
this pathway.32 Even after 17 hours, we did not witness complete reaction of the starting 
macrocycle 4 (ca. 10 % remaining).  LC/MS analysis revealed a broad range of 
components, most of which seemed to result from indiscriminate degradation of either 4 
or the expected photocleavage product 37.  The mixture was concentrated by passing a 
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stream of air over the surface of the solution until dry, and then the residue was dissolved 
in water to be purified via HPLC. Unfortunately, no single compound could be isolated in 
 
 
 
sufficient quantity for further evaluation after the attempted purification. The experiment 
was repeated with a 1.5 mg sample of 4 that gave similar results. Again, the main 
components of the mixture after irradiation were compounds 2 and 37, but nothing could 
be isolated. 
It was somewhat disheartening that we were unable to isolate a clean product 
from these trials. In order to gain more evidence that the photochemical degradation of 
macrocycle 3 was preceding in a similar fashion to the bis sulfur analogues, we next 
performed the photolysis via irradiation with 254 nm light in a mixture of n-propyl 
alcohol and water using an IR cell with CaF lenses (insoluble in water) to verify the 
products by IR signal. Pleasingly, the net difference in IR absorption before and after 5 
hours of irradiation clearly revealed two new signals at 2223 cm-1 and 2156 cm-1, 
characteristic of the cyanamide and thiocyanate functionalities, respectively (Figure 
2.25). We also tracked the decrease in UV absorbance @ 265 nm during the course of the 
photolysis experiment by irradiating 350 µg of 4 in 3 mL of 2:1 acetonitrile and water 
with  UV-C  bulbs (λmax = 254 nm) in  a quartz cuvette  (Figure 2.26).  With  this spectral  
Figure 2.24. Investigation of S,N-tetrazine photochemistry, first attempt 
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Figure 2.25. Net difference in IR spectrum after 5 hours of irradiation 
Figure 2.26. UV-Vis absorption during the photolysis of 4 
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evidence bolstering our confidence that the photochemical fragmentation of the S,N-
tetrazine  moiety was  proceeding  as we originally  proposed, we turned  our thoughts  to 
proposed product 37 (Figure 2.24). The only difference between this structure and the 
structures resulting from photolysis of the bis sulfur substituted tetrazines was the 
presence of the cyanamide moiety. A search of the literature revealed three different 
degradation pathways this functional group could be susceptible to under these conditions 
(Figure 2.27).33  
The remainder of our efforts concerning the photolysis reaction of macrocycle 4 
were  focused  on  attempting  to  develop a  strategy  to trap  compound  37 and  isolate a 
stable product. Some of the structures we hoped to be able to produce are shown in 
Figure 2.28. Along with these trapping strategies, we tried irradiating macrocycle 3 at 
different wavelengths and using different solvent mixtures during the reaction. 
Unfortunately, none of these strategies bore fruit. Clearly, the photochemistry of the S,N-
tetrazine staples was more complicated than that of the S,S-tetrazine staples previously 
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Figure 2.27. Degradation pathways of cyanamides;33 A) isomerization to 
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developed in the Smith group and, as time was running short, further studies were 
considered outside the scope of this thesis.1,,24,37-39 
 
 
 
 
 
 
Summary 
 The goal of this Thesis work was to take methods previously developed by Brown 
and Smith1 for the use of dichloro-s-tetrazine in the creation of stapled peptides and to 
investigate how far that method could be extended to include residues other than cysteine. 
In the course of this investigation, we developed a method for the successful creation of 
stapled peptides using a single cysteine and single lysine residue (seven example 
explored, 20 – 54% yield over the two steps).  Although this method lacked the general 
tolerance and applicability of the method previously developed for two cysteine residues 
we were pleased that some stapling with a cysteine / lysine peptide is possible.  
Unfortunately we found that this method could not be successfully extended to include 
serine, threonine, or tyrosine.19 Reagrding the photochemistry of the newly created S,N-
tetrazine macrocycles, we demonstrated by IR analysis that macrocycle 4 does in fact 
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undergo photochemical dissociation in a similar fashion to the previous work of Brown 
and Smith,1 although isolation of definable products proved unsuccessful. Although this 
answer was not as positive as we might have hoped, these results clearly demonstrate the 
limited breath this chemistry can be extended with respect to peptide systems, thus 
answering the question we originally set out to investigate. 
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CHAPTER 3 – SCALE UP PREPARATION OF DICHLORO-
S-TETRAZINE (1) 
 The synthesis of dichloro-s-tetrazine (1) was first reported by Schirmer and 
coworkers in 1986 as part of a search for new herbicides.1 This synthesis was achieved by 
reacting   dimethylthio-s-tetrazine   (38)2   with   chlorine   gas  Figure  3.1. Compound  1 
 
 
 
 
 
 
reappeared in the literature in 1998 when Sparey and Harrison first reported examples of 
using 1 as a substrate in the inverse electron demand Diels Alder reaction between 
tetrazines and unsaturated compounds, originally communicated by Carboni and 
Lindsey.3-4 The synthesis of 1 was reported again in 1999 as part of Chavez and Hiskey’s 
ongoing search for high nitrogen content energetic materials.5 While Chavez and 
Hiskey’s report made good use of the advances made by Coburn and coworkers in the 
synthesis of 3,6-diamino-s-tetrazine by using 3,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)-s-
tetrazine  (39, Figure 3.2)6-7 as  a  replacement  for  the  difficult  to  access  38,  the  final  
Figure 3.1. Original synthesis of dichloro-s-tetrazine (1)1 from dimethylthio-s-tetrazine 
(38)2 
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conversion from 3,6-dihydrazineyl-s-tetrazine (40) to dichloro-s-tetrazine (1) again made 
use of chlorine gas.5 In 2006, Helm and coworkers  communicated a useful  modification 
to that procedure by  replacing chlorine gas with the much more mild 
trichloroisocyanuric acid (41) (Figure 3.3).8 The switch to this much safer and more 
efficient oxidant (as it can be weighed and transferred  as  a  dry  solid  and  be  stored  on  
a  shelf  at  room  temperature) made the synthesis of dichloro-s-tetrazine much more 
accessible.9 Another important modification came from Gong and coworkers when they  
communicated  the  replacement  of  NO2  gas  with  sodium  nitrite  in  the formation of 
3,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)-s-tetrazine (39) in 2006 (Figure 3.4).10  
Figure 3.2. Chavez and Hiskey’s synthesis of dichloro-s-tetrazine (1)5 using 
Coburn and coworker’s intermediate (39)7 
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 Both 1 and 39 are often featured in the literature as versatile synthons for the 
synthesis   of   tetrazines  via   SNAr    displacement.11-13   The   s-tetrazine   chromophore 
continues to provide new avenues of research on photoactive high explosives from the 
Los Alamos National Laboratory in the constant search for new high - energy 
materials.14-19 In the biological realm, dichloro-s-tetrazine (1) has been used as a starting 
point for the synthesis of stapled peptides and proteins,20-24 site-specific dual-labeling of 
peptides and proteins,25 and the templated synthesis of ternary biological constructs.26 In 
drug delivery, in inverse electron demand Diels Alder reaction has been used in to 
Figure 3.3. Modified synthesis of dichloro-s-tetrazine (1) using trichloroisocyanuric acid 
(41); It is worth noting that the authors purified 1 by sublimation rather than filtration 
through celite. As 1 is thermally unstable, the low yield can be attributed to the method of 
purification.8 
Figure 3.4. Use of sodium nitrite for the synthesis of 3,6-bis(3,5-dimethyl-1H-pyrazol-1-
yl)-s-tetrazine (41)10  
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develop a “click to release” strategy pairing antibody-guided delivery of a drug molecule, 
the release of which is triggered by tetrazine ligation.27-31 In small molecule organic 
chemistry, 1 continues to be a source of new fluorophores,10-11,13,32-33 a partner in cross-
coupling reactions,34-35 and a building block for materials chemistry.36-37  
Despite this frequent and widely varied usage, no one has communicated a 
verified scalable procedure for the synthesis of 3,6-dichloro-s-tetrazine (1). Having scaled 
up the procedure communicated by Gong and coworkers, we sought to fill this need by 
submitting a safe, scalable synthetic protocol to Organic Synthesis, as we believe this 
represents the most reliable route to the production of dichloro-s-tetrazine available today 
(Figure 3.5).  The steps  from guanidine  hydrochloride (42) through  the formation of 44  
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Figure 3.5.  Full route for the synthesis of dichloro-s-tetrazine (1) 
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were first reported by Coburn and coworkers.7 The only modification made to these steps 
was the addition of an aqueous workup for the isolation of 44 rather than the original 
method of filtration followed by drying in vacuo. While this added separation 
necessitates additional solvent usage, raising the environmental impact of the process, it 
dramatically accelerates access to pure, dry 44. The transformation from 44 to 39 was 
first communicated by Gong and coworkers using chemistry that had been previously 
applied to tetrazine syntheses following the Pinner route.10,38 While the gaseous nitric 
oxide oxidation communicated by Coburn and coworkers works faster, gaseous nitric 
oxide and Dreschel’s Bottle reaction vessels are not as common in synthetic laboratories 
as they once were. The in situ generation of nitrous acid via sodium nitrite and acetic acid 
communicated by Gong uses much more common reagents to achieve the same 
transformation in comparable yield (>90%) and is therefore much more generally 
accessible.10 The transformation from 39 to 40 was communicated by Chavez and 
Hiskey, who also made several different salts of 40 and determined that the material 
could be handled relatively safely under 120°C through differential thermal analysis.5 
The method for final transformation to dichloro-s-tetrazine (1) was originally 
communicated by Helm and coworkers.8 The use of trichloroisocyanuric acid (41) as 
chlorine source and oxidant is preferable because 41 is a bench stable, free flowing 
powder and therefore much more safe and accessible than chlorine gas cylinders.  
Pleasingly, this final step is the only one that involves detailed purification. We found 
that multiple passes of the reaction mixture through a celite plug provides adequately 
pure material (only 1 carbon detectable by 13C NMR). However, 1 can be purified further 
by vacuum sublimation if rigorously pure material should be required.  
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EXPERIMENTAL 
Reaction Equipment. Peptides were synthesized on a Liberty BlueTM Automated 
Microwave Peptide Synthesizer (CEM Corporation). N-terminus capping reactions and 
cleavage from resin were performed in peptide synthesis vessels (20 – 30 mL) fit with 
coarse fritted glass support and Teflon stopcocks. Peptide synthesis vessels were agitated 
on a Lab Line Mistral Multi-Mixer (Model 4600). Photochemical Experiments were 
performed in a RayonetTM Srinivasan-Griffin Photoreactor (The Southern New England 
Untraviolet Company) using light sources at 420 nm (LuzChwem [LZC-420]), 350-385 
nm (Southern New England Ultraviolet Company [RPR-3500A]), 315 nm (Sankyo Denki 
[G8TSE]), or 254 nm (Southern New England Ultraviolet Company [RPR-2537A]).  
Chromatography. Preparatory-scale reverse-phase chromatography was performed with 
a Gilson 215 liquid handler/injector fitted with a Gilson binary HPLC pump system 
(model 333/334) and a Gilson UV/Vis dual wavelength detector (model 156). Gilson 
TrilutionTM LC software was used as the control interface for the described instrument 
configuration. Chromatographies were carried out on a Waters SunfireTM Prep C18 5 µm 
OBDTM, 19mm ID x 100 mm column (Part No. 186002567), or a Vydac Preperative C18 
10 µm, 300 Å, 22 mm ID x 100 mm column (Cat. No. 218TP1022). The eluent was 
acetonitrile (HPLC grade, Fisher Chemical) and Milli-Q water, purified from facility DI 
water with a Millipore SimplicityTM water purification system (Cat. No. SIMS00000) 
equipped with a SimpliPakTM 1 filter (Millipore, Cat. No. SIPK0SIA1), with a 0.1% 
trifluoroacetic acid buffer unless otherwise noted. Gradients and flow rate were 
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compound-specific. Peptides were isolated using a Labconco Freezone 12 Plus 
lyophilizer modified to run off an Edwards 28 2-stage vacuum pump. 
Instruments Used for Obtaining Spectral Data. 1D and 2D NMR spectra were 
recorded on a Bruker Avance III equipped with a 5 mm DCH CyroProbe platform. The 
low-resolution LC-MS analyses were conducted using a Waters AcquityTM UPLC system 
equipped with an SQ detector for mass analysis and a TUV detector for optical analysis. 
The LC-MS samples were analyzed as solutions in water or acetonitrile, prepared at 0.15 
– 0.20 mg/mL concentration. The LC-MS chromatography was carried out on a Water 
AcquityTM HSS-C18 column (2.1 x 50 mm; 1.8 µm; Part No. 188003532) with linear 
gradients of 0.10% formic acid in acetonitrile and 0.10% formic acid water. Accurate 
mass measurement was obtained on Waters LC-TOF mass spectrometer (model LCT-XE 
Premier) using electrospray ionization in positive or negative mode, depending upon the 
analyte. Waters software calibrates and reports by use of neutral atomic masses. The 
mass of the electron is not included. All FTIR spectra were taken on a Nicolet 6700 FTIR 
spectrometer or PerkinElmer FTIR (model Spectrum BX). 
General Resin Washing Procedure. Resin washing was conducted with the indicated 
volume of named solvent and repeated as described. Each wash was allowed to contact 
resin beads for ~30 seconds. At the end of each washing cycle, the solvent was pushed 
through the frit of the peptide synthesis vessel using a barbed inlet air adapter with a 
14/20 male ground glass joint. In peptide synthesis vessels without a ground glass joint, a 
neoprene rubber filter adapter was added to facilitate a tight seal.  
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General Procedure for Manual Solid – Phase Peptide Synthesis 
Manual Solid Phase Peptide Synthesis. Designated resin was weighed out and placed in 
a clean, dry peptide synthesis vessel. Resin was swollen with ~4mL of DCM for 30 
minutes. Resin was washed with DMF (2 x 2mL), a solution of 20% piperidine in DMF 
(2 x 5mL, allowing each wash to contact resin for 10 minutes before being drained), and 
DMF (5 x ~4mL). A premixed solution (coupling cocktail) of fmoc-protected amino acid, 
Oxyma, HBTU, and DIPEA in 5mL of semi-dry (stored over 4Å sieves) DMF was added 
to the resin and the vessel was gently rocked for 1 hour. The coupling cocktail was 
drained; resin was washed with DMF (2 x 3mL), 20% piperidine in DMF solution (2 x 
5mL, allowing each wash to contact resin for 10 minutes before draining), and DMF (5 x 
~4 mL). The next coupling cocktail was then added. The cycle of coupling cocktail 
mixing and addition, 1 hour of gentle rocking, and subsequent washes was repeated for 
each amino acid in the peptide. After the last DMF was sequence, the resin was washed 
with DCM (2 x 5 mL) and stored under vacuum.  
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General Procedure for Automated Solid Phase Peptide Synthesis. 
Solid Phase Peptide Synthesis (SPPS). Peptides were synthesized on a CEM Liberty 
Blue microwave assisted automated peptide synthesizer. All couplings were done with 
the “standard coupling procedure” included in the liberty blue software. Deprotetion 
solution was 10 g of piperidine in 10 mL of ethanol and 90 mL of N-methyl-pyrrolidone. 
Coupling reagents were N,N’-diisopropylcarbodiimide and 1-hydroxybenzotriazole 
monohydrate. N-terminus was left fully protected at the end of the synthesis. The resin-
bound peptide was transferred to a peptide synthesis vessel, washed with DMF (2 x 5 
mL) and DCM (2 x 5 mL), and stored under vacuum. 
General Procedure for N-terminus Peptide Capping 
 
N-terminus Peptide Capping. The peptide synthesis vessel containing the resin-bound 
peptide was removed from the vacuum line and the resin was swelled in DCM (~7 mL) 
for 1 hour. The solvent was drained and the resin was washed with DMF (2 x 5 mL). The 
premixed Fmoc deprotection solution consisting of 20% piperidine in DMF (5 mL) was 
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added to the synthesis vessel and allowed to maintain contact with the resin for 10 
minutes before being drained from the vessel. This deprotection cycle was repeated 
twice, after which the resin was washed with DMF (5 x 5 mL). A premixed capping 
solution consisting of acetic anhydride (20 equivalents) and pyridine (20 equivalents) in 
DMF (6 mL) was added to the peptide synthesis vessel and was allowed to maintain 
contact with the resin for 1 hour with gentle oscillation on a Mistral Multi-Mixer (Lab 
Line Instruments). After 1 hour, the capping solution was drained and the resin was 
washed with DMF (2 x 5 mL) and DCM (2 x 5 mL) and stored under vacuum.  
General Procedure for Peptide Cleavage and Global Deprotection 
 
Peptide Cleavage and Global Deprotection. The peptide synthesis vessel containing the 
resin bound peptide was removed from the vacuum line. DCM (~7 mL) was added to the 
vessel and the resin was swelled for 1 hour. The DCM was drained and 7 mL of a 
premixed peptide cleavage cocktail (9 mL TFA, 0.5 mL EDT, 0.25 mL H2O, and 0.25 
mL TIPSH) was added to the vessel. The cleavage cocktail was allowed to make contact 
with the resin beads for 4 hours while the vessel was subjected to gentle rocking. The 
solution was drained into a 50 mL round bottom flask and the remaining cleavage 
cocktail (~3 mL) was used to wash the beads before also being drained into the round 
bottom flask. The combined cleavage cocktail was concentrated under reduced pressure 
and the crude peptide was precipitated from solution by the addition of diethyl ether. The 
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crude peptide was isolated by vacuum filtration in a cintered glass funnel and dried in 
vacuo. Each peptide was then purified by HPLC as indicated.  
 
 
 
 
 
Peptide 2. Prepared by automated SPPS from Rink Amide AM resin (0.49 mmol, 1.05 g) 
according to the procedures given above. Isolated residue was dissolved in 4 mL of Milli-
Q water and purified by reverse-phase chromatography (gradient 5 – 50% organic over 5 
minutes at a 20 mL/minute flow rate) on the Gilson HPLC setup with the Sunfire column 
discussed above. Fractions were collected with 210 nm detection with a 20 mV threshold. 
After lyophilization, compound was isolated as 167.1 mg (78%) of amorphous white 
powder as the TFA salt: AMM (ESI) Found m/z 362.1866 [(M+H)+; calcd for 
C14H28N5O4S: 362.1862]; 1H NMR (500 MHz, DMSO-d6) δ 8.23 (d, J = 6.9 Hz, 1H), 
8.12 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.64 (s, 3H), 7.29 (d, J = 2.1 Hz, 1H), 
7.07 (d, J = 2.1 Hz, 1H), 4.37 (td, J = 7.6, 5.4 Hz, 1H), 4.23 (p, J = 7.1 Hz, 1H), 4.14 (td, 
J = 8.6, 5.0 Hz, 1H), 2.76 (ddd, J = 12.0, 8.9, 5.7 Hz, 3H), 2.69 – 2.60 (m, 1H), 2.41 (t, J 
= 8.5 Hz, 1H), 2.36 (p, J = 1.9 Hz, 1H), 1.87 (s, 3H), 1.66 (ddd, J = 13.8, 10.8, 6.0 Hz, 
1H), 1.49 (p, J = 7.9, 6.7 Hz, 3H), 1.34 – 1.26 (m, 1H), 1.22 (d, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, DMSO) δ 173.44, 171.97, 171.06, 169.95, 169.68, 158.19, 115.97, 
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55.08, 52.09, 48.69, 40.02, 39.85, 39.69, 39.52, 39.35, 39.19, 39.02, 38.73, 31.46, 26.68, 
26.52, 26.19, 22.56, 22.24, 17.84, 17.74, 17.33; IR (KBr, cm-1) 3283 (br), 3198 (w), 3072 
(w), 2934 (w), 1675 (s), 1621 (s), 1539 (s), 1424 (s), 1393 (w), 1373 (s), 1289 (w), 1200 
(s), 1187 (s), 1135 (s), 838 (w), 800 (w), 722 (s), 691 (s), 625 (s), 600 (s). 
 
 
 
 
 
Peptide 10a. Prepared by automated SPPS from Rink Amide AM resin (0.513 mmol, 
1.09 g) according to the procedures given above. Isolated residue was dissolved in 2 mL 
of Milli-Q water, 2 mL of acetonitrile, and 2 mL of trifluoroacetic acid before being 
purified by reverse-phase chromatography (gradient 10 – 70% organic over 8 minutes at 
a 20 mL/minute flow rate) on the Gilson HPLC setup with the Sunfire column discussed 
above. Fractions were collected with 210 nm detection with a 20 mV threshold. After 
lyophilization, compound was isolated as 144 mg (33%) of amorphous white powder as 
the TFA salt: AMM (ESI) Found m/z 750.3990 [(M+H)+; calcd for C34H56N9O8S: 
750.3973]; 1H NMR (500 MHz, DMSO-d6) δ 8.19 – 7.99 (m, 5H), 7.88 – 7.83 (m, 2H), 
7.66 (s, 4H), 7.35 (s, 1H), 7.27 – 7.15 (m, 6H), 7.08 (s, 1H), 4.52 (td, J = 8.8, 4.5 Hz, 
1H), 4.37 – 4.10 (m, 4H), 3.72 (d, J = 5.7 Hz, 2H), 3.04 (dd, J = 14.1, 4.5 Hz, 1H), 2.90 – 
2.71 (m, 3H), 2.71 – 2.64 (m, 2H), 2.24 (t, J = 8.6 Hz, 1H), 1.83 (s, 3H), 1.74 – 1.65 (m, 
1H), 1.60 (h, J = 6.7 Hz, 1H), 1.49 (ddd, J = 23.4, 11.5, 5.3 Hz, 6H), 1.37 – 1.21 (m, 1H), 
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1.17 (d, J = 7.1 Hz, 5H), 0.85 (dd, J = 24.5, 6.5 Hz, 6H). 13C NMR (126 MHz, DMSO) δ 
173.46, 172.47, 172.25, 170.85, 169.46, 169.30, 168.53, 157.91 (q, J = 31.2 Hz), 137.58, 
129.21, 128.09, 126.31, 117.17 (q, J = 299.6 Hz), 54.83, 53.91, 52.03, 51.22, 48.29, 
48.25, 42.07, 40.78, 38.73, 37.14, 31.33, 26.66, 26.21, 24.02, 23.10, 22.51, 22.49, 22.27, 
21.58, 18.04, 17.70. IR (KBr, cm-1) 3269 (br), 3054 (br), 2926 (br), 1626 (s), 1522 (s), 
1198 (s), 1177 (w), 1130 (w), 830 (w), 796 (w), 699 (w), 695 (w).  
 
 
 
 
 
 
Peptide 10b. Prepared by automated SPPS from Rink Amide AM resin (0.46 mmol, 1.08 
g) according to the procedures given above. Isolated residue was dissolved in 7 mL of 
Milli-Q water and 3 mL acetonitrile before being purified by reverse-phase 
chromatography (gradient 5 – 60% organic over 8 minutes at a 20 mL/minute flow rate) 
on the Gilson HPLC setup with the Sunfire column discussed above. Fractions were 
collected with 210 nm detection with a 5 mV threshold. After lyophilization, compound 
was isolated as 301 mg (68%) of amorphous white powder as the TFA salt: AMM (ESI) 
Found m/z 766.3945 [(M+H)+; calcd for C34H56N9O9S: 766.3922]; 1H NMR (500 
MHz, DMSO-d6) δ 9.20 (s, 1H), 8.13 (d, J = 7.1 Hz, 1H), 8.10 (d, J = 7.2 Hz, 1H), 8.03 
(dd, J = 6.9, 3.9 Hz, 2H), 7.99 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.85 (d, J = 
8.1 Hz, 1H), 7.66 (s, 3H), 7.35 (s, 1H), 7.10 (s, 1H), 7.01 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 
8.5 Hz, 2H), 4.41 (td, J = 8.5, 4.5 Hz, 1H), 4.32 (td, J = 7.4, 5.4 Hz, 1H), 4.24 (ddt, J = 
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14.2, 12.5, 7.4 Hz, 3H), 4.15 (td, J = 8.6, 4.9 Hz, 1H), 3.78 – 3.65 (m, 2H), 2.91 (dd, J = 
14.1, 4.5 Hz, 1H), 2.80 – 2.62 (m, 5H), 2.26 (t, J = 8.6 Hz, 1H), 1.83 (s, 3H), 1.69 (ddt, J 
= 13.9, 9.5, 5.6 Hz, 1H), 1.60 (hept, J = 6.7 Hz, 1H), 1.49 (tdd, J = 14.9, 12.1, 10.8, 6.4 
Hz, 5H), 1.28 (dq, J = 16.5, 8.8, 8.2 Hz, 2H), 1.18 (dd, J = 7.1, 4.9 Hz, 6H), 0.87 (d, J = 
6.6 Hz, 3H), 0.82 (d, J = 6.4 Hz, 3H); 13C NMR (126 MHz, DMSO) δ 173.50, 172.51, 
172.29 (2C), 171.03, 169.45, 169.32, 168.55, 158.00 (q, J = 30.6 Hz), 155.83, 130.15, 
127.56, 117.28 (q, J = 300.5 Hz),114.89, 54.89, 54.30, 52.05, 51.21, 48.33, 48.26, 42.09, 
40.75, 38.74, 36.37, 31.33, 26.67, 26.24, 24.01, 23.11, 22.53, 22.29, 21.58, 18.06, 17.71; 
IR (KBr, cm-1) 3274 (br), 3073 (br), 2932 (br), 1625 (s), 1529 (s), 1443 (w), 1201 (s), 
1138 (br), 834 (w), 800 (w), 721 (s), 619 (w), 551 (w). 
 
 
 
 
 
 
Peptide 10c. Prepared by automated SPPS from Rink Amide AM resin (0.513 mmol, 
1.09 g) according to the procedures given above. Isolated residue was dissolved in 2 mL 
of Milli-Q water, 1 mL of acetonitrile, and 1 mL of trifluoroacetic acid before being 
purified by reverse-phase chromatography (gradient 10 – 50% organic over 7 minutes at 
a 20 mL/minute flow rate) on the Gilson HPLC setup with the Sunfire column discussed 
above. Fractions were collected with 210 nm detection with a 20 mV threshold. After 
lyophilization, compound was isolated as 125 mg (32%) of amorphous white powder as 
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the TFA salt: AMM (ESI) Found m/z 712.3452 [(M+Na)+; calcd for C28H51N9O9SNa: 
712.3428]; 1H NMR (500 MHz, DMSO-d6) δ 8.16 – 8.06 (m, 3H), 8.03 (dd, J = 10.7, 7.7 
Hz, 2H), 7.95 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.67 (s, 3H), 7.33 (s, 1H), 
7.07 (s, 1H), 5.06 (s, 1H), 4.42 (q, J = 7.3 Hz, 1H), 4.34 – 4.19 (m, 4H), 4.14 (td, J = 8.6, 
4.9 Hz, 1H), 3.69 (dd, J = 16.9, 5.9 Hz, 2H), 3.59 (ddd, J = 27.0, 10.6, 5.9 Hz, 2H), 2.74 
(dp, J = 13.7, 7.6, 6.2 Hz, 4H), 2.37 (t, J = 8.5 Hz, 1H), 1.83 (s, 3H), 1.66 (dtq, J = 33.4, 
12.9, 6.5 Hz, 2H), 1.49 (dt, J = 14.2, 6.5 Hz, 5H), 1.34 – 1.15 (m, 8H), 0.85 (dd, J = 23.1, 
6.5 Hz, 6H); 13C NMR (126 MHz, DMSO) δ 173.50, 172.47, 172.40, 172.35, 170.03, 
169.69, 169.29, 168.55, 158.01 (q, J = 31.2 Hz), 117.21 (q, J = 299.9 Hz), 61.49, 55.17, 
54.77, 52.08, 51.38, 48.33, 48.20, 42.13, 40.52, 38.75, 31.29, 26.66, 26.26, 24.08, 23.12, 
22.52, 22.29, 21.49, 18.06, 17.76; IR (KBr, cm-1) 3276 (br), 3055 (br), 2926 (br), 1627 
(s), 1520 (s) 1419 (w), 1200 (s), 1172 (w), 1130 (w), 1062 (w), 951 (w), 807 (w), 761 
(w), 718 (w), 667 (w). 
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Peptide 10d. Prepared by automated SPPS from Rink Amide AM resin (0.506 mmol, 
1.08 g) according to the procedures given above. Isolated residue was dissolved in 4 mL 
of Milli-Q water before being purified by reverse-phase chromatography (gradient 10 – 
60% organic over 6 minutes at a 20 mL/minute flow rate) on the Gilson HPLC setup with 
the Sunfire column discussed above. Fractions were collected with 210 nm detection with 
a 20 mV threshold. After lyophilization, compound was isolated as 239 mg (54%) of 
amorphous white powder as the TFA salt: AMM (ESI) Found m/z 781.4138 [(M+Na)+; 
calcd for C31H58N12O8NaS: 781.4119]; 1H NMR (500 MHz, DMSO-d6) δ 8.20 – 8.09 (m, 
3H), 8.07 (d, J = 7.6 Hz, 1H), 7.95 (d, J = 7.5 Hz, 2H), 7.89 (d, J = 8.0 Hz, 1H), 7.78 (s, 
3H), 7.67 (t, J = 5.4 Hz, 1H), 7.52 – 6.91 (m, 6H), 4.37 (q, J = 7.1 Hz, 1H), 4.31 – 4.18 
(m, 4H), 4.14 (td, J = 8.4, 5.1 Hz, 1H), 3.81 – 3.67 (m, 2H), 3.08 (q, J = 6.4 Hz, 2H), 2.75 
(q, J = 7.6 Hz, 4H), 2.38 (t, J = 8.6 Hz, 1H), 1.83 (s, 3H), 1.76 – 1.39 (m, 11H), 1.38 – 
1.09 (m, 8H), 0.96 – 0.70 (m, 6H); 13C NMR (126 MHz, DMSO) δ 173.56, 172.61, 
172.46, 172.35, 171.15, 169.70, 169.49, 168.63, 158.66 (q, J = 31.8 Hz), 156.83, 117.05 
(q, J = 298.6 Hz), 54.98, 52.43, 52.17, 51.14, 48.42, 42.01, 40.87, 40.43, 38.72, 31.36, 
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28.86, 26.69, 26.11, 25.02, 24.11, 23.11, 22.53, 22.31, 21.54, 17.98, 17.70; IR (KBr, cm-
1) 3270 (br), 3047 (br), 2931 (br), 1653 (s), 1521 (s), 1417 (w), 1366 (w), 1200 (s), 1175 
(s), 1129 (s), 831 (w), 798 (w), 718 (w).  
 
 
 
 
 
Peptide 19. Prepared by automated SPPS from Rink Amide AM resin (0.509 mmol, 1.08 
g) according to the procedures given above. Isolated residue was dissolved in 10 mL of 
Milli-Q water before being purified by reverse-phase chromatography (gradient 5 – 75% 
organic over 9 minutes at a 20 mL/minute flow rate) on the Gilson HPLC setup with the 
Sunfire column discussed above. Fractions were collected with 210 nm detection with a 5 
mV threshold. After lyophilization, compound was isolated as 133 mg (23%) of 
amorphous white powder as the TFA salt: AMM (ESI) Found m/z 517.7574 [(M+H)+; 
calcd for C34H56N9O9S: 517.7586]; 1H NMR (500 MHz, DMSO-d6) δ 8.25 (t, J = 5.8 Hz, 
1H), 8.21 – 8.12 (m, 2H), 7.92 (d, J = 7.9 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.71 (s, 3H), 
7.37 (s, 1H), 7.22 (s, 1H), 4.42 – 4.18 (m, 4H), 3.83 – 3.57 (m, 2H), 2.97 – 2.65 (m, 5H), 
2.54 – 2.40 (m, 1H), 2.26 (dd, J = 9.0, 7.8 Hz, 1H), 2.03 (s, 3H), 1.94 – 1.86 (m, 1H), 
1.85 (s, 3H), 1.76 (dtt, J = 11.2, 7.6, 3.8 Hz, 1H), 1.67 (tt, J = 14.0, 5.9 Hz, 1H), 1.59 – 
1.46 (m, 4H), 1.39 – 1.19 (m, 4H); 13C NMR (126 MHz, DMSO) δ 172.15, 171.95, 
171.49, 171.40, 169.81, 168.88, 158.11 (q, J = 31.7 Hz), 117.06 (q, J= 299.3 Hz), 54.63, 
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52.21, 52.19, 48.58, 42.10, 40.02, 38.75, 31.41, 31.33, 29.58, 26.69, 26.17, 22.55, 22.19, 
17.59, 14.58; IR (KBr, cm-1) 3284 (br), 3072 (w), 2932 (w), 1625 (s), 1537 (s) 1436 (w), 
1291 (s), 1201 (s), 1166 (s), 1134 (w), 836 (w), 800 (w), 721 (w), 618 (w). 
 
 
 
 
Peptide 32. Prepared by manual SPPS from Rink Amide resin (0.5 mmol, 1.09 g) 
according to the procedures given above. Isolated residue was dissolved in 10 mL of a 
1:4 mix of water/acetonitrile before being purified by reverse-phase chromatography 
(gradient 5 – 60% organic over 6 minutes at a 20 mL/minute flow rate) on the Gilson 
HPLC setup with the Sunfire column discussed above. Fractions were collected with 210 
nm detection with a 20 mV threshold. After lyophilization, compound was isolated as 98 
mg (38%) of amorphous white powder: AMM (ES) Found m/z 511.1959 [(M+H)+; calcd 
for C21H31N6O7S: 511.1975]; 1H NMR (500 MHz, DMSO-d6) δ 9.17 (s, 1H), 8.29 (t, J = 
5.8 Hz, 1H), 8.19 – 8.09 (m, 2H), 8.02 (d, J = 7.1 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.37 
(s, 1H), 7.08 (s, 1H), 6.99 (d, J = 8.3 Hz, 2H), 6.62 (d, J = 8.2 Hz, 2H), 4.41 – 4.28 (m, 
2H), 4.24 (p, J = 7.1 Hz, 1H), 3.72 (p, J = 5.9 Hz, 3H), 3.56 (dd, J = 16.6, 5.6 Hz, 1H), 
2.88 (dd, J = 13.9, 4.8 Hz, 1H), 2.76 (ddd, J = 13.9, 8.7, 5.5 Hz, 1H), 2.66 (ddd, J = 13.8, 
11.7, 5.3 Hz, 2H), 2.44 (t, J = 8.5 Hz, 1H), 1.87 (s, 3H), 1.20 (d, J = 7.1 Hz, 3H); 13C 
NMR (126 MHz, DMSO) δ 173.03, 172.49, 170.36, 169.73, 168.54, 168.36, 155.76, 
130.09, 128.02, 114.90, 55.30, 54.24, 48.38, 42.06, 41.95, 36.83, 26.02, 22.57, 18.10; IR 
(KBr, cm-1) 3287 (br), 1624 (s), 1516 (s) 1439 (w), 1234 (w), 831 (w), 603 (w).  
O
O
N
H
HS OH
N
O
N
H
OH
N
O
N
H
OH
NH2
32
	
	
82	
 
 
 
 
Peptide SI-1. Prepared by automated SPPS from Rink Amide resin (0.503 mmol, 1.09 g) 
according to the procedures given above. Isolated residue was dissolved in 8 mL of Milli-
Q water before being purified by reverse-phase chromatography (gradient 10 – 90% 
organic over 10 minutes at a 15 mL/minute flow rate) on the Gilson HPLC setup with the 
Sunfire column discussed above. Fractions were collected with 210 nm detection with a 
20 mV threshold. After lyophilization, compound was isolated as 194 mg (46%) of 
amorphous white powder as the TFA salt: AMM (ESI) Found m/z 660.3517 [(M+H)+; 
calcd for C27H50N9O8S: 660.3503]; 1H NMR (500 MHz, DMSO-d6) δ 8.25 (t, J = 5.8 Hz, 
1H), 8.20 (t, J = 5.7 Hz, 1H), 8.14 (d, J = 7.1 Hz, 1H), 8.10 (d, J = 7.1 Hz, 1H), 7.99 (d, J 
= 7.8 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 8.2 Hz, 1H), 7.69 (s, 3H), 7.34 (s, 
1H), 7.08 (s, 1H), 4.36 (td, J = 7.3, 5.3 Hz, 1H), 4.31 – 4.20 (m, 3H), 4.14 (td, J = 8.6, 4.9 
Hz, 1H), 3.79 – 3.64 (m, 4H), 2.79 – 2.70 (m, 3H), 2.48 – 2.43 (m, 1H), 1.83 (s, 3H), 1.73 
– 1.36 (m, 7H), 1.35 – 1.10 (m, 8H), 0.90 – 0.80 (m, 6H); 13C NMR (126 MHz, DMSO) δ 
173.48, 172.54, 172.40, 172.32, 169.88, 169.36, 168.68, 168.59, 158.03 (q, J = 31.3 Hz), 
117.10 (q, J = 299.3 Hz), 54.95, 52.04, 51.18, 48.34, 48.27, 42.11, 42.05, 40.74, 38.73, 
31.30, 26.65, 26.17, 24.08, 23.04, 22.52, 22.24, 21.61, 18.03, 17.61; IR (KBr, cm-1) 3380 
(br), 3270 (br), 3043 (br), 2921 (br), 2858 (w), 1627 (s), 1521 (s), 1419 (w), 1199 (s), 
1171 (s), 1127 (s), 832 (w), 798 (w), 720 (w), 668 (w). 
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Peptide SI-2. Prepared by automated SPPS from Rink Amide resin (0.503 mmol, 1.09 g) 
according to the procedures given above. Isolated residue was dissolved in 8 mL of Milli-
Q water and 4 mL of trifluoroacetic acid before being purified by reverse-phase 
chromatography (gradient 10 – 90% organic over 10 minutes at a 15 mL/minute flow 
rate) on the Gilson HPLC setup with the Sunfire column discussed above. Fractions were 
collected with 210 nm detection with a 20 mV threshold. After lyophilization, compound 
was isolated as 268 mg (60%) of amorphous white powder as the TFA salt: AMM (ESI) 
Found m/z 766.3912 [(M+H)+; calcd for C34H56N9O9S: 766.3922]; 1H NMR (500 MHz, 
DMSO-d6) δ 9.17 (s, 1H), 8.22 (d, J = 7.1 Hz, 1H), 8.15 – 8.08 (m, 2H), 8.05 – 7.94 (m, 
3H), 7.83 (d, J = 8.1 Hz, 1H), 7.63 (s, 3H), 7.33 (s, 1H), 7.08 (s, 1H), 7.03 (d, J = 8.4 Hz, 
2H), 6.63 (d, J = 8.0 Hz, 2H), 4.46 – 4.34 (m, 2H), 4.34 – 4.20 (m, 3H), 4.15 (td, J = 8.7, 
4.8 Hz, 1H), 3.71 (d, J = 5.6 Hz, 2H), 2.87 (dd, J = 14.0, 4.2 Hz, 1H), 2.80 – 2.66 (m, 
4H), 2.65 – 2.53 (m, 1H), 2.44 – 2.35 (m, 1H), 1.79 – 1.56 (m, 5H), 1.56 – 1.39 (m, 5H), 
1.37 – 1.14 (m, 8H), 0.91 – 0.77 (m, 6H); 13C NMR (126 MHz, DMSO) δ 173.45, 
172.35, 172.29, 172.12, 171.60, 169.30, 169.27, 168.56, 157.76 (d, J = 30.4 Hz), 155.73, 
130.07, 128.08, 117.39 (d, J = 301.0 Hz), 114.83, 54.73, 54.28, 52.04, 51.24, 48.34, 
42.07, 40.71, 38.75, 36.66, 31.28, 26.64, 26.26, 24.09, 23.06, 22.99, 22.49, 22.28, 21.59, 
17.83, 17.81; IB (KBr, cm-1) 3280 (br), 2982 (br), 2937 (br), 2928 (br), 2870 (w), 1628 
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(s), 1516 (s), 1442 (s), 1365 (w), 1215 (w), 1200 (s), 1174 (s), 1133 (s), 832 (w), 798 (w), 
720 (w).  
 
 
 
 
Peptide SI-3. Prepared by automated SPPS from Rink Amide resin (0.502 mmol, 1.07 g) 
according to the procedures given above. Isolated residue was dissolved in 4 mL  Milli-Q 
water, 4 mL trifluoroacetic acid, and 2 mL acetonitrile before being purified by reverse-
phase chromatography (gradient 10 – 60% organic over 60 minutes at a 15 mL/minute 
flow rate) on the Gilson HPLC setup with the Sunfire column discussed above. Fractions 
were collected with 210 nm detection with a 20 mV threshold. After lyophilization, 
compound was isolated as 100 mg (32%) of amorphous white powder as the TFA salt: 
AMM (ESI) Found m/z 504.2617 [(M+H)+; calcd for C20H38N7O6S: 504.2604]; 1H NMR 
(500 MHz, DMSO-d6) δ 8.21 (d, J = 6.9 Hz, 1H), 8.11 (d, J = 7.7 Hz, 1H), 7.98 (d, J = 
7.1 Hz, 1H), 7.92 (d, J = 7.0 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.62 (s, 3H), 7.25 (s, 1H), 
7.07 (s, 1H), 4.37 (q, J = 7.4 Hz, 1H), 4.26 – 4.17 (m, 3H), 4.13 (td, J = 8.4, 5.3 Hz, 1H), 
2.75 (hept, J = 6.7, 6.2 Hz, 3H), 2.65 (dt, J = 13.5, 7.9 Hz, 1H), 2.40 (t, J = 8.4 Hz, 1H), 
1.87 (s, 3H), 1.71 – 1.62 (m, 1H), 1.50 (h, J = 7.1, 6.3 Hz, 3H), 1.35 – 1.14 (m, 12H); 13C 
NMR (126 MHz, DMSO) δ 173.35, 172.08, 172.03, 171.89, 169.85, 169.58, 54.99, 
52.00, 48.49, 48.38, 48.31, 38.75, 31.40, 26.66, 26.15, 22.53, 22.18, 17.89, 17.84, 17.77; 
IR (KBr, cm-1) 3361 (br), 3275 (br), 3193 (br), 3060 (br), 2969 (br), 2928 (br), 2867 (br), 
2767 (br), 2655 (br), 2546 (br), 1669 (s), 1623 (s), 1533 (s), 1443 (s), 1419 (s), 1375 (s), 
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1373 (s), 1284 (w), 1200 (s), 1174 (s), 1132 (s), 1057 (w), 1036 (w), 963 (w), 916 (w), 
835 (w), 798 (w), 721 (w), 599 (w). 
 
 
 
 
Peptide SI-4. Prepared by automated SPPS from Rink Amide AM resin (0.507 mmol, 
994 mg) according to the procedures given above. Isolated residue was dissolved in 6 mL 
of Milli-Q water and 2 mL of trifluoroacetic acid before being purified by reverse-phase 
chromatography (gradient 1 – 30% organic over 8 minutes at a 20 mL/minute flow rate) 
on the Gilson HPLC setup with the Sunfire column discussed above. Fractions were 
collected with 210 nm detection with a 20 mV threshold. After lyophilization, compound 
was isolated as 119 mg (40%) of amorphous white powder as the TFA salt: AMM (ESI) 
Found m/z 476.2289 [(M+H)+; calcd for C18H34N7O6S: 476.2291]; 1H NMR (500 MHz, 
DMSO-d6) δ 8.30 (t, J = 5.8 Hz, 1H), 8.22 – 8.14 (m, 2H), 8.03 (d, J = 7.0 Hz, 1H), 7.80 
(d, J = 8.2 Hz, 1H), 7.64 (s, 3H), 7.32 (s, 1H), 7.08 (s, 1H), 4.33 (td, J = 7.5, 5.5 Hz, 1H), 
4.24 (p, J = 7.0 Hz, 1H), 4.15 (td, J = 8.7, 4.8 Hz, 1H), 3.81 – 3.65 (m, 4H), 2.81 – 2.62 
(m, 4H), 2.45 (t, J = 8.5 Hz, 1H), 1.88 (s, 3H), 1.74 – 1.64 (m, 1H), 1.57 – 1.44 (m, 3H), 
1.35 – 1.13 (m, 5H); 13C NMR (126 MHz, DMSO) δ 173.48, 172.62, 170.42, 169.82, 
168.66, 168.60, 157.82 (q, J = 30.6 Hz), 117.33 (d, J = 300.9 Hz), 55.37, 52.02, 48.46, 
42.17, 42.09, 38.74, 31.23, 26.62, 25.94, 22.56, 22.23, 17.92; IR (KBr, cm-1) 3374 (br), 
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3279 (br), 3051 (br), 2917 (br), 1623 (s), 1522 (s), 1419 (w), 1195 (s), 1172 (s), 1127 (s), 
831 (w), 797 (w), 717 (w).  
 
 
 
 
 
Peptide SI-5. Prepared by manual SPPS from Rink Amide resin (0.15 mmol, 255 mg) 
according to the procedures given above. Isolated residue was dissolved in 50/50 mix of 
water/acetonitrile before being purified by reverse-phase chromatography (gradient 5 – 
40% organic over 10 minutes at a 20 mL/minute flow rate) on the Gilson HPLC setup 
with the Vydac column discussed above. Fractions were collected with 224 nm detection 
with a 20 mV threshold. After lyophilization, compound was isolated as 168 mg (70%) of 
amorphous white powder as the TFA salt: AMM (ES) Found m/z 865.4714 [(M+H)+; 
calcd for C38H65N12O9S: 865.4718];  1H NMR (500 MHz, DMSO-d6) δ 9.14 (s, 1H), 8.05 
(dd, J = 12.0, 7.6 Hz, 2H), 8.00 (d, J = 8.1 Hz, 2H), 7.89 – 7.86 (m, 2H), 7.83 (d, J = 8.4 
Hz, 1H), 7.69 – 7.60 (m, 5H), 7.31 (s, 1H), 7.20 (s, 1H), 7.14 (s, 1H), 7.05 (s, 1H), 7.00 
(d, J = 8.4 Hz, 2H), 6.87 (s, 1H), 6.75 (s, 1H), 6.61 (d, J = 8.4 Hz, 2H), 4.56 – 4.42 (m, 
2H), 4.37 – 4.26 (m, 2H), 4.17 (dtd, J = 29.5, 14.0, 7.8 Hz, 4H), 3.63 – 3.49 (m, 1H), 2.91 
(dd, J = 14.1, 4.2 Hz, 1H), 2.79 – 2.52 (m, 4H), 2.40 (dd, J = 15.7, 7.0 Hz, 1H), 2.20 (t, J 
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= 8.4 Hz, 1H), 2.10 (t, J = 7.9 Hz, 2H), 2.07 – 2.00 (m, 1H), 1.92 – 1.57 (m, 11H), 1.57 – 
1.36 (m, 6H), 1.26 (d, J = 25.2 Hz, 3H), 1.17 (d, J = 6.9 Hz, 3H), 1.08 (dt, J = 14.8, 7.8 
Hz, 1H), 0.89 (d, J = 6.5 Hz, 3H), 0.86 – 0.78 (m, 11H); 13C NMR (126 MHz, DMSO) δ 
173.95, 173.44, 171.82, 171.75, 171.38, 171.00, 170.99, 170.89, 170.72, 170.31, 169.85, 
169.48, 155.74, 130.12, 127.69, 114.83, 59.74, 56.98, 54.93, 54.19, 52.30, 52.06, 51.61, 
49.49, 46.71, 46.63, 38.78, 36.83, 36.53, 36.21, 31.41, 31.20, 28.88, 27.84, 26.55, 26.04, 
24.49, 24.35, 24.25, 23.05, 22.45, 22.18, 22.08, 21.49, 16.79, 15.34, 10.99; IR (KBr, cm-
1) 3425 (br), 3285 (br), 2965 (w), 2924 (w), 2843 (w), 1654 (s), 1636 (s), 1517 (s), 1458 
(w), 1231 (s), 1209 (s), 1155 (s). 
 
 
 
 
 
Peptide SI-6. Prepared by automated SPPS from Rink Amide AM resin (0.509 mmol, 
1.08 g) according to the procedures given above. Isolated residue was dissolved in 10 mL 
of Milli-Q water before being purified by reverse-phase chromatography (gradient 5 – 
75% organic over 9 minutes at a 20 mL/minute flow rate) on the Gilson HPLC setup with 
the Sunfire column discussed above. Fractions were collected with 210 nm detection with 
a 5 mV threshold. After lyophilization, compound was isolated as 133 mg (23%) of 
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amorphous white powder as the TFA salt: AMM (ESI) Found m/z 517.7574 [(M+2H)2+; 
calcd for C34H56N9O9S: 517.7586]; 1H NMR (500 MHz, DMSO-d6) δ 9.20 (s, 1H), 8.27 
(t, J = 5.7 Hz, 1H), 8.20 (d, J = 7.8 Hz, 1H), 8.11 – 8.02 (m, 3H), 7.91 (t, J = 7.9 Hz, 2H), 
7.70 (d, J = 8.8 Hz, 4H), 7.34 (s, 1H), 7.28 (s, 1H), 7.18 (s, 1H), 7.09 (s, 1H), 7.00 (d, J = 
8.5 Hz, 2H), 6.93 (s, 1H), 6.82 (s, 1H), 6.62 (d, J = 8.5 Hz, 2H), 4.58 – 4.43 (m, 2H), 
4.42 – 4.31 (m, 2H), 4.30 – 4.20 (m, 2H), 4.13 (ddd, J = 16.9, 14.1, 8.1 Hz, 2H), 3.72 (qd, 
J = 16.6, 5.7 Hz, 2H), 3.55 (ddt, J = 25.8, 9.9, 6.7 Hz, 2H), 2.93 (dd, J = 14.0, 4.4 Hz, 
1H), 2.78 – 2.65 (m, 4H), 2.62 – 2.52 (m, 2H), 2.39 (dd, J = 15.6, 7.6 Hz, 1H), 2.23 (t, J 
= 8.5 Hz, 1H), 2.14 – 1.97 (m, 3H), 1.91 – 1.43 (m, 13H), 1.36 – 1.20 (m, 2H), 1.16 (d, J 
= 6.9 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H), 0.82 (d, J = 6.4 Hz, 3H); 13C NMR (126 MHz, 
DMSO) δ 174.02, 173.48, 171.86, 171.77, 171.50, 171.40, 171.09, 170.72, 170.45, 
170.06, 169.63, 168.83, 158.51 (q, J = 32.5 Hz), 155.83, 130.16, 127.68, 117.26 (q, J = 
298.0 Hz), 114.88, 59.70, 54.97, 54.53, 52.18, 52.06, 51.57, 49.54, 46.72, 46.63, 42.13, 
3978, 38.76, 36.85, 36.45, 31.37, 31.26, 28.96, 27.98, 26.60, 26.04, 24.53, 24.26, 23.11, 
22.53, 22.24, 21.52, 16.78; IR (KBr, cm-1) 3288 (br), 3190 (br), 2950 (br), 1652 (s), 1441 
(s), 1201 (s), 1175 (s), 1134 (s), 800 (w), 721 (w), 596 (w). 
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Peptide SI-7. Prepared by automated SPPS from Rink Amide AM resin (0.509 mmol, 
1.08 g) according to the procedures given above. Isolated residue was dissolved in 3 mL 
of Milli-Q water and 1 mL of acetonitrile before being purified by reverse-phase 
chromatography (gradient 5 – 75% organic over 8 minutes at a 20 mL/minute flow rate) 
on the Gilson HPLC setup with the Sunfire column discussed above. Fractions were 
collected with 210 nm detection with a 5 mV threshold. After lyophilization, compound 
was isolated as 170 mg (50%) of amorphous white powder as the TFA salt: AMM (ESI) 
Found m/z 553.2295 [(M+H)+; calcd for C21H41N6O5S3: 553.2301]; 1H NMR (500 MHz, 
DMSO-d6) δ 8.25 (d, J = 6.8 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 8.02 (d, J = 7.6 Hz, 1H), 
7.97 (d, J = 8.0 Hz, 1H), 7.63 (s, 3H), 7.38 (s, 1H), 7.25 (s, 1H), 4.38 (qd, J = 8.0, 5.1 Hz, 
2H), 4.29 – 4.16 (m, 2H), 3.10 (dd, J = 12.9, 5.0 Hz, 1H), 2.97 (dd, J = 13.0, 8.6 Hz, 1H), 
2.79 – 2.70 (m, 3H), 2.69 – 2.65 (m, 1H), 2.39 (t, J = 8.5 Hz, 1H), 1.88 (s, 3H), 1.72 – 
1.63 (m, 1H), 1.59 – 1.44 (m, 3H), 1.39 – 1.26 (m, 11H), 1.23 (d, J = 7.1 Hz, 3H); 13C 
NMR (126 MHz, DMSO) δ 172.44, 171.43, 171.32, 169.92, 169.60, 157.75 (d, J = 30.4 
Hz), 117.34 (d, J = 300.8 Hz), 54.95, 52.62, 52.01, 48.62, 47.78, 42.47, 38.76, 31.11, 
29.59, 26.60, 26.20, 22.57, 22.14, 17.76; IR (KBr, cm-1) 3285 (br), 3073 (br). 2963 (br), 
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1623 (s), 1536 (s), 1427 (w), 1287 (w), 1201 (s), 1178 (s), 1135 (s), 836 (w), 799 (w), 
721 (s), 618 (w), 595 (w).  
 
 
 
 
 
Peptide SI-8. Prepared by manual SPPS from Rink Amide resin (0.20 mmol, 465 mg) 
according to the procedures given above. Isolated residue was dissolved in Milli-Q water 
and purified by reverse-phase chromatography (gradient 5 – 75% organic over 10 
minutes at a 20 mL/minute flow rate) on the Gilson HPLC setup with the Vydac column 
discussed above. Fractions were collected with 210 nm detection with a 20 mV threshold. 
After lyophilization, compound was isolated as 100.1 mg (81%) of amorphous white 
powder as the TFA salt: AMM (ES) Found m/z 528.2222 [(M+Na)+; calcd for 
C19H35N7O7SNa: 528.2216]; 1H NMR (500 MHz, DMSO-d6) δ 8.45 (d, J = 7.5 Hz, 1H), 
8.21 (d, J = 7.7 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.73 (s, 3H), 7.69 (d, J = 7.9 Hz, 1H), 
7.51 (s, 1H), 7.17 (s, 1H), 7.13 (s, 1H), 7.00 (s, 1H), 5.04 (s, 1H), 4.61 (q, J = 6.9 Hz, 
1H), 4.37 (q, J = 7.1 Hz, 1H), 4.14 (ddd, J = 20.3, 8.5, 4.0 Hz, 2H), 4.07 (dd, J = 6.5, 4.0 
Hz, 1H), 2.76 (ddq, J = 14.0, 8.7, 5.3, 4.7 Hz, 3H), 2.64 (ddd, J = 22.3, 15.5, 7.4 Hz, 2H), 
2.47 (dd, J = 15.5, 6.5 Hz, 1H), 2.36 (t, J = 8.5 Hz, 1H), 1.89 (s, 3H), 1.73 (tt, J = 10.4, 
5.0 Hz, 1H), 1.56 (ddd, J = 21.8, 12.3, 5.9 Hz, 2H), 1.49 (d, J = 7.0 Hz, 1H), 1.30 (dddt, J 
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= 27.1, 22.9, 11.2, 6.8 Hz, 2H), 1.05 (d, J = 6.3 Hz, 3H); 13C NMR (126 MHz, DMSO) δ 
173.71, 171.83, 171.19, 170.08, 169.78, 169.63, 66.33, 58.34, 55.17, 52.43, 49.89, 38.73, 
36.62, 30.84, 26.61, 26.15, 22.51, 22.39, 19.55; IR (KBr, cm-1) 3401 (br), 3250 (br), 3210 
(br), 3075 (br), 2980 (br), 1671 (s), 1654 (s), 1540 (s), 1534 (s), 1415 (w), 1240 (w), 110 
(w), 930 (w), 884 (w).  
 
 
 
 
 
Peptide SI-9. Prepared by manual SPPS from Rink Amide resin (0.20 mmol, 465 mg) 
according to the procedures given above. Isolated residue was dissolved in 8 mL of Milli-
Q water and 7 mL of acetonitrile before being purified by reverse-phase chromatography 
(gradient 20 – 60% organic over 15 minutes at a 20 mL/minute flow rate) on the Gilson 
HPLC setup with the Vydan column discussed above. Fractions were collected with 210 
nm detection with a 20 mV threshold. After lyophilization, compound was isolated as 
91.4 mg (73%) of amorphous white powder as the TFA salt: AMM (ES) Found m/z 
865.4714 [(M+H)+; calcd for C38H65N12O9S: 865.4718]; 1H NMR (500 MHz, DMSO-d6) 
δ 9.43 – 8.99 (m, 3H), 8.10 (dd, J = 11.8, 7.0 Hz, 2H), 8.02 – 7.90 (m, 3H), 7.87 (d, J = 
7.7 Hz, 1H), 7.79 (q, J = 7.3, 6.3 Hz, 3H), 7.65 (t, J = 5.7 Hz, 1H), 7.52 – 6.75 (m, 10H), 
6.62 (d, J = 8.1 Hz, 3H), 4.41 (td, J = 8.7, 4.1 Hz, 1H), 4.35 – 4.18 (m, 4H), 4.15 (td, J = 
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8.2, 5.0 Hz, 1H), 3.10 (q, J = 6.6 Hz, 2H), 2.92 (dd, J = 14.3, 4.1 Hz, 1H), 2.81 – 2.62 (m, 
4H), 2.25 (t, J = 8.6 Hz, 1H), 1.84 (s, 3H), 1.78 – 1.38 (m, 10H), 1.38 – 1.12 (m, 7H), 
0.85 (dd, J = 21.5, 6.5 Hz, 6H); 13C NMR (126 MHz, DMSO) δ 173.30, 172.56, 172.35, 
172.01, 170.97, 170.94, 169.52, 169.41, 158.51 (q, J = 31.4 Hz), 156.82, 155.82, 130.04, 
127.54, 117.08 (q, J = 299.2 Hz), 114.88, 55.05, 54.35, 52.21, 52.14, 51.17, 48.43, 48.40, 
40.68, 40.45, 38.66, 36.29, 31.40, 28.83, 26.63, 26.03, 24.92, 24.04, 23.08, 22.47, 22.17, 
21.51, 17.89, 17.55; IR (KBr, cm-1)  3422 (br), 2957 (br), 2937 (br), 2172 (w), 1640 (s), 
1525 (s), 1437 (w) 1374 (w), 1209 (s), 1155 (s), 1018 (br), 823 (w), 803 (w). 
 
General Procedure for Modifying Peptides with Dichloro-s-tetrazine 
 
 
 
 
Procedure for modifying peptides with dichloro-s-tetrazine. Purified peptide (as TFA 
salt) was dispensed into a round bottom flask equipped with a magnetic stir bar and 
dissolved in Milli-Q water. Dichloro-s-tetrazine was weighed into a separate test tube and 
dissolved in acetonitrile. The ratio of the two solvents was 9 /1 water / acetonitrile and 
the volume of the combined mix was enough to make a 1 mM solution of the purified 
peptide. The total volume of the reaction should not exceed half the volume of the round 
bottom flask. The solution of dichloro-s-tetrazine was poured into the round bottom flask 
and the reaction mixture was vigorously stirred for 2 minutes. The stir bar was removed 
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and the flask was attached to a rotary evaporator. The water bath of the rotary evaporator 
was replaced with a dry ice/acetone bath and the reaction mixture was frozen in a thin 
film about the flask. The frozen flask was placed inside a lyophilizer jar and dried in 
vacuo via lyophilization. 
 
General Procedure for Macrocyclization of Acyclic Dichloro-s-tetrazine Peptides 
 
 
 
Macrocyclization of Acyclic Dichloro-s-tetrazine Peptides. Isolated material recovered 
from the lyophilizer was reconstituted in 9 / 1 mix of NaHCO3 buffer (made with Milli-Q 
water, pH 8.5, 25 mM) / acetonitrile. A magnetic stir bar was added and the reaction was 
allowed to stir for 2 hours before the stir bar was removed and the contents of the flask 
were frozen as described in the general procedure for modifying peptides with 
dichloro-s-tetrazine. After drying the contents of the flask were reconstituted and 
purified as described.   
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Macrocycle 3. Prepared from Peptide 2 (0.099 mmol, 47.3 mg) as described above in 
general procedure for modifying peptides with dichloro-s-tetrazine and general 
procedure for macrocyclization of acyclic dichloro-s-tetrazine peptides. Isolated 
residue was dissolved in 7 mL of trifluoroacetic acid and 3 mL of Milli-Q water before 
being purified by reverse-phase chromatography (gradient 5 – 95% organic over 10 
minutes at a 20 mL/minute flow rate) on the Gilson HPLC setup with the Sunfire column 
discussed above. Fractions were collected with 210 nm detection with a 20 mV threshold. 
After lyophilization, compound was isolated as 42.7 mg (48%) of amorphous orange 
powder: AMM (ES) Found m/z 440.1828 [(M+H)+; calcd for C16H26N9O4S]; 1H NMR 
(500 MHz, DMSO-d6, 1% v/v TMS) δ 8.37 (t, J = 6.3 Hz, 1H), 8.13 (d, J = 7.4 Hz, 1H), 
8.08 (d, J = 7.7 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.24 (s, 1H), 6.95 (s, 1H), 4.64 (td, J = 
7.3, 3.4 Hz, 1H), 4.18 (td, J = 9.9, 8.9, 3.5 Hz, 1H), 4.06 (p, J = 7.0 Hz, 1H), 3.68 (ddt, J 
= 13.7, 6.8, 3.5 Hz, 1H), 3.63 – 3.46 (m, 2H), 3.28 – 3.17 (m, 1H), 1.89 (s, 3H), 1.78 – 
1.59 (m, 2H), 1.56 – 1.46 (m, 1H), 1.46 – 1.35 (m, 1H), 1.35 – 1.26 (m, 1H), 1.26 – 1.14 
(m, 2H), 1.10 (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, DMSO) δ 173.82, 170.98, 
169.08, 167.92, 163.35, 160.93, 52.84, 51.21, 47.73, 31.96, 31.11, 30.76, 27.45, 22.52, 
22.07, 19.62, 1.16; IR (KBr, cm-1) 3405 (br), 3292 (br), 3054 (w), 2924 (br), 2854 (br), 
1653 (s), 1636 (s), 1560 (s), 1522 (s), 1437 (w), 1196 (w), 1042 (w), 938 (w). 
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Macrocycle 12c. Prepared from Peptide 10c (0.0549 mmol, 44.1 mg) as described above 
in general procedure for modifying peptides with dichloro-s-tetrazine and general 
procedure for macrocyclization of acyclic dichloro-s-tetrazine peptides. Isolated 
residue was dissolved in 3 mL of Milli-Q water, 1 mL of trifluoroacetic acid, and 2 mL of 
acetonitrile before being purified by reverse-phase chromatography (gradient 10 – 70% 
organic over 8 minutes at a 15 mL/minute flow rate) on the Gilson HPLC setup with the 
Sunfire column discussed above. Fractions were collected with 210 nm detection with a 
20 mV threshold. After lyophilization, compound was isolated as 15.7 mg (37%) of 
amorphous orange powder: AMM (ES) Found m/z 768.3575 [(M+H)+; calcd for 
C30H50N13O9S]; 1H NMR (500 MHz, DMSO-d6) δ 8.45 (t, J = 6.2 Hz, 1H), 8.28 (d, J = 
6.8 Hz, 1H), 8.21 (d, J = 6.8 Hz, 1H), 8.16 – 8.05 (m, 2H), 7.90 (t, J = 6.0 Hz, 1H), 7.68 
– 7.56 (m, 2H), 7.13 (s, 1H), 7.02 (s, 1H), 4.53 (td, J = 6.9, 5.2 Hz, 1H), 4.25 (td, J = 7.1, 
5.1 Hz, 2H), 4.20 – 4.13 (m, 1H), 4.05 (td, J = 9.1, 8.4, 4.0 Hz, 1H), 3.96 (dt, J = 7.3, 4.8 
Hz, 2H), 3.68 – 3.26 (m, 9H), 1.83 (s, 3H), 1.74 – 1.39 (m, 7H), 1.32 – 1.13 (m, 8H), 0.90 
– 0.80 (m, 6H); 13C NMR (126 MHz, DMSO) δ 173.76, 173.06, 172.75, 172.46, 170.10, 
170.00, 169.34, 168.48, 163.75, 160.76, 60.95, 56.30, 52.70, 52.23, 51.84, 48.59, 48.23, 
41.99, 40.37, 39.58, 32.45, 30.99, 27.81, 24.07, 23.04, 22.61, 22.50, 21.53, 18.00, 17.47; 
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IR (KBr, cm-1) 3295 (br), 3052 (br), 2936 (br), 2930 (br), 2865 (s), 1653 (s), 1560 (s), 
1522 (br), 1457 (s), 1374 (s), 1197 (s), 1170 (w), 1129 (w), 1041 (w), 936 (w). 
 
 
 
 
 
 
 
Macrocycle 12d. Prepared from Peptide 10d (0.106 mmol, 104.8 mg) as described 
above in general procedure for modifying peptides with dichloro-s-tetrazine and 
general procedure for macrocyclization of acyclic dichloro-s-tetrazine peptides. 
Isolated residue was dissolved in 3 mL of Milli-Q water, 1 mL of trifluoroacetic acid, and 
2 mL of acetonitrile before being purified by reverse-phase chromatography (gradient 5 – 
70% organic over 8 minutes at a 15 mL/minute flow rate) on the Gilson HPLC setup with 
the Sunfire column discussed above. Fractions were collected with 210 nm detection with 
a 20 mV threshold. After lyophilization, compound was isolated as 61.7 mg (37%) of 
amorphous orange powder as the TFA salt: AMM (ES) Found m/z 837.4274 [(M+H)+; 
calcd for C33H57N16O8S]; 1H NMR (500 MHz, DMSO-d6) δ 8.45 (t, J = 6.2 Hz, 1H), 8.26 
(d, J = 6.7 Hz, 2H), 8.16 (d, J = 6.8 Hz, 2H), 7.92 (t, J = 6.1 Hz, 1H), 7.70 (d, J = 8.2 Hz, 
1H), 7.62 (d, J = 7.5 Hz, 1H), 7.47 (t, J = 5.8 Hz, 1H), 7.43 – 6.61 (m, 5H), 4.47 (q, J = 
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6.7 Hz, 1H), 4.29 – 4.10 (m, 3H), 4.09 – 3.91 (m, 2H), 3.72 – 3.57 (m, 4H), 3.39 – 3.32 
(m, 2H), 3.16 – 3.00 (m, 2H), 1.86 (s, 3H), 1.79 – 1.39 (m, 11H), 1.23 (t, J = 7.0 Hz, 9H), 
0.96 – 0.72 (m, 6H); 13C NMR (126 MHz, DMSO) δ 173.78, 173.19, 173.09, 172.45, 
171.34, 170.26, 169.74, 168.44, 163.66, 160.83, 158.06 (q, J = 31.7 Hz), 156.64, 53.47, 
52.80, 52.25, 51.61, 48.92, 48.72, 41.97, 40.40, 40.35, 40.20, 32.11, 30.88, 28.47, 27.84, 
25.05, 24.22, 23.05, 22.56, 22.53, 21.42, 17.76, 17.38; IR (KBr, cm-1) 3318 (br), 3060 
(br), 2951 (br), 2930 (br), 2867 (w), 1653 (s), 1552 (s), 1533 (s), 1448 (w), 1437 (w), 
1369 (w), 1200 (s), 1174 (s), 1131 (s), 1042 (w), 940 (w), 831 (w), 798 (w), 668 (w).  
 
 
 
 
Macrocycle 13. Prepared from Peptide SI-1 (0.0677 mmol, 52.4 mg) as described above 
in general procedure for modifying peptides with dichloro-s-tetrazine and general 
procedure for macrocyclization of acyclic dichloro-s-tetrazine peptides. Isolated 
residue was dissolved in 3 mL of Milli-Q water and 3 mL of trifluoroacetic acid before 
being purified by reverse-phase chromatography (gradient 10 – 65% organic over 20 
minutes at a 15 mL/minute flow rate) on the Gilson HPLC setup with the Sunfire column 
discussed above. Fractions were collected with 210 nm detection with a 20 mV threshold. 
After lyophilization, compound was isolated as 26 mg (52%) of amorphous orange 
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powder: AMM (ES) Found m/z 760.3317 [(M+Na)+; calcd for C29H47N13O8NaS]; 1H 
NMR (500 MHz, DMSO-d6) δ 8.52 (t, J = 6.1 Hz, 1H), 8.33 (t, J = 6.0 Hz, 1H), 8.19 (t, J 
= 6.2 Hz, 2H), 8.12 – 8.06 (m, 2H), 7.78 (d, J = 6.9 Hz, 1H), 7.57 (d, J = 8.1 Hz, 1H), 
7.15 (s, 1H), 7.03 (s, 1H), 4.47 (q, J = 6.1 Hz, 1H), 4.31 – 4.21 (m, 2H), 4.15 – 4.01 (m, 
2H), 3.81 – 3.69 (m, 1H), 3.63 – 3.33 (m, 7H), 1.84 (s, 3H), 1.75 – 1.40 (m, 7H), 1.38 – 
1.13 (m, 8H), 0.95 – 0.76 (m, 6H); 13C NMR (126 MHz, DMSO) δ 173.75, 172.82, 
172.60, 172.40, 169.94, 169.34, 169.32, 168.63, 163.60, 160.61, 52.97, 52.53, 52.20, 
48.45, 48.25, 42.73, 42.14, 39.77, 39.71, 32.51, 31.26, 28.34, 24.15, 22.88, 22.86, 22.52, 
21.58, 18.10, 17.43; IR (KBr, cm-1) 3287 (br), 3054 (br), 2936 (s), 2930 (s), 2867 (s), 
1653 (s), 1523 (s), 1437 (s), 1369 (s), 1326 (w), 1194 (s), 1167 (s), 1042 (w), 939 (w), 
690 (w), 543 (w). 
 
 
 
 
Macrocycle 14. Prepared from Peptide SI-2 (0.0507 mmol, 44.6 mg) as described above 
in general procedure for modifying peptides with dichloro-s-tetrazine and general 
procedure for macrocyclization of acyclic dichloro-s-tetrazine peptides. Isolated 
residue was dissolved in 3 mL of Milli-Q water, 2 mL of trifluoroacetic acid, and 1 mL of 
acetonitrile before being purified by reverse-phase chromatography (gradient 10 – 70% 
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organic over 20 minutes at a 15 mL/minute flow rate) on the Gilson HPLC setup with the 
Sunfire column discussed above. Fractions were collected with 210 nm detection with a 
20 mV threshold. After lyophilization, compound was isolated as 16.4 mg (38%) of 
amorphous orange powder: AMM (ES) Found m/z 844.3905 [(M+H)+; calcd for 
C36H54N13O9S]; 1H NMR (500 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.46 (t, J = 6.2 Hz, 1H), 
8.34 (dd, J = 8.7, 6.5 Hz, 2H), 8.19 (d, J = 6.9 Hz, 1H), 8.05 (d, J = 8.1 Hz, 1H), 7.90 (t, J 
= 5.9 Hz, 1H), 7.62 (d, J = 7.8 Hz, 2H), 7.13 – 6.96 (m, 3H), 6.64 (d, J = 8.4 Hz, 2H), 
4.50 – 4.38 (m, 2H), 4.22 (p, J = 7.0 Hz, 1H), 4.11 (ddd, J = 10.0, 7.2, 4.9 Hz, 1H), 4.03 
(td, J = 9.5, 8.6, 3.9 Hz, 1H), 3.90 (p, J = 7.1 Hz, 2H), 3.68 – 3.57 (m, 3H), 3.57 – 3.41 
(m, 2H), 3.36 (dd, J = 13.4, 6.6 Hz, 1H), 3.02 – 2.90 (m, 1H), 2.63 (dd, J = 14.1, 10.3 Hz, 
1H), 1.84 – 1.67 (m, 4H), 1.66 – 1.39 (m, 6H), 1.37 – 1.11 (m, 8H), 0.95 – 0.76 (m, 6H); 
13C NMR (126 MHz, DMSO) δ 173.71, 173.21, 172.61, 172.46, 172.10, 169.80, 169.41, 
168.53, 163.72, 160.64, 155.73, 130.02, 128.12, 114.85, 54.22, 53.00, 52.38, 51.92, 
49.36, 48.96, 42.13, 40.15, 39.92, 36.54, 32.45, 30.96, 27.87, 24.22, 22.97, 22.77, 22.49, 
21.52, 17.36, 17.26; IR (KBr, cm-1) 3290 (br), 3061 (br), 2948 (s), 2930 (s), 2860 (s), 
1653 (s), 1516 (s), 1447 (s), 1368 (s), 1337 (w), 1253 (s), 1232 (s), 1200 (s), 1132 (s), 
1042 (w), 940 (w), 832 (w), 797 (w), 719 (w), 668 (w). 
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Macrocycle 15. Prepared from Peptide SI-3 (0.0489 mmol, 30.2 mg) as described above 
in general procedure for modifying peptides with dichloro-s-tetrazine and general 
procedure for macrocyclization of acyclic dichloro-s-tetrazine peptides. Isolated 
residue was dissolved in 3 mL of Milli-Q water and 3 mL of trifluoroacetic acid before 
being purified by reverse-phase chromatography (gradient 10 – 50% organic over 8 
minutes at a 15 mL/minute flow rate) on the Gilson HPLC setup with the Sunfire column 
discussed above. Fractions were collected with 210 nm detection with a 20 mV threshold. 
After lyophilization, compound was isolated as 17.8 mg (63%) of amorphous orange 
powder: AMM (ES) Found m/z 582.2568 [(M+H)+; calcd for C22H36N11O6S]; 1H NMR 
(500 MHz, DMSO-d6) δ 8.57 – 8.50 (m, 2H), 8.47 (d, J = 6.5 Hz, 1H), 7.75 (d, J = 6.4 
Hz, 1H), 7.57 (d, J = 6.6 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.06 (s, 1H), 6.87 (s, 1H), 
4.38 (q, J = 5.5 Hz, 1H), 4.10 – 3.96 (m, 4H), 3.73 (p, J = 7.1 Hz, 1H), 3.62 – 3.44 (m, 
3H), 3.32 (dq, J = 13.2, 6.4 Hz, 1H), 1.92 (s, 3H), 1.79 – 1.68 (m, 1H), 1.64 – 1.45 (m, 
3H), 1.37 – 1.11 (m, 10H); 13C NMR (126 MHz, DMSO) δ 173.69, 172.76, 172.64, 
171.95, 170.88, 170.44, 163.70, 160.46, 54.09, 52.70, 49.54, 49.41, 48.87, 39.97, 32.73, 
31.08, 27.94, 23.02, 22.72, 17.24, 17.06, 16.60; IR (KBr, cm-1) 3286 (br), 3050 (w), 2959 
O
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(w), 2927 (br), 2857 (w), 1653 (s), 1534 (s), 1457 (s), 1373 (s), 1192 (s), 1169 (s), 1042 
(w), 938 (w). 
 
 
 
Macrocycle 10d. Prepared from Peptide SI-4 (0.0555 mmol, 32.7 mg) as described 
above in general procedure for modifying peptides with dichloro-s-tetrazine and 
general procedure for macrocyclization of acyclic dichloro-s-tetrazine peptides. 
Isolated residue was dissolved in 3 mL of Milli-Q water and 1 mL of trifluoroacetic acid 
before being purified by reverse-phase chromatography (gradient 5 – 50% organic over 
10 minutes at a 15 mL/minute flow rate) on the Gilson HPLC setup with the Sunfire 
column discussed above. Fractions were collected with 210 nm detection with a 20 mV 
threshold. After lyophilization, compound was isolated as 6.1 mg (20%) of amorphous 
orange powder: AMM (ES) Found m/z 576.2088 [(M+Na)+; calcd for C20H31N11O6NaS]; 
1H NMR (500 MHz, DMSO-d6) δ 8.53 (t, J = 6.1 Hz, 1H), 8.47 – 8.39 (m, 2H), 8.01 (t, J 
= 6.1 Hz, 1H), 7.93 (d, J = 6.2 Hz, 1H), 7.56 (d, J = 8.2 Hz, 1H), 7.11 (s, 1H), 7.03 (s, 
1H), 4.47 (q, J = 6.3 Hz, 1H), 4.13 – 3.99 (m, 2H), 3.76 – 3.67 (m, 2H), 3.60 (d, J = 5.6 
Hz, 1H), 3.58 – 3.55 (m, 1H), 3.55 – 3.53 (m, 1H), 3.52 – 3.34 (m, 7H, contains water), 
1.90 (s, 3H), 1.76 – 1.65 (m, 1H), 1.64 – 1.44 (m, 4H), 1.38 – 1.19 (m, 7H); 13C NMR 
(126 MHz, DMSO) δ 173.74, 172.71, 170.31, 170.23, 169.27, 168.62, 163.64, 160.57, 
O
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53.09, 52.57, 49.38, 42.75, 42.12, 39.91, 32.78, 31.14, 28.27, 22.87, 22.59, 17.27; IR 
(KBr, cm-1) 3294 (br), 3053 (br), 2930 (s), 2853 (w), 1652 (s), 1543 (s), 1538 *s(, 1435 
(w), 1414 (w), 1405 (w), 1372 (w), 1353 (w), 1333 (w), 1195 (w), 1124 (w), 1042 (w), 
1012 (w), 942 (w). 
 
	
	
	
Triaminoguanidine hydrochloride (43). A 2 L, 2-neck round bottom flask equipped 
with a reflux condenser was charged with guanidine•hcl (88.8 g, 0.9292 mol) and 1,4-
dioxane (400 mL). The mixture was magnetically stirred and hydrazine hydrate (3.07 
mol, 152 mL) was added. After the addition, all solids had dissolved. The reaction 
mixture was heated to 100°C with magnetic stirring for two hours, during which time a 
white solid precipitated from the solution. The flask was removed from heat and stirring 
was halted, allowing the contents to room temperature and settle. The solid was collected 
by vacuum filtration and washed with 500 mL of Et2O. Filtrate was dried in vacuo for 3 
hours, and then the solid was ground to a fine powder in a mortar and pestle. The solid 
was then dried overnight to yield 128.2 g (98%) of triaminoguanidine hydrochloride (26) 
as a white crystalline solid. 13C NMR (126 MHz, D2O) δ = 159.7; IR (KBr, cm-1) 3308 
(s), 3179 (br), 2760 (br), 2630 (br), 2542 (br), 2444 (br), 2298 (br), 2056 (s), 1994 (w), 
1817 (w), 1667 (s), 1602 (s), 1315 (s), 1118 (s0, 936 (br), 731 (s), 600 (br). 
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3,6-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,4-dihydro-1,2,4,5-tetrazine (44). A 3-neck, 3 
L round bottom flask was equipped with a mechanical stirrer and placed in an oil bath. 
The flask was charged with triaminoguanidium hydrochloride (0.91 mol, 128 g) and DI-
water (1 L). The stirrer was turned on and the solid dissolved. 2,4-Pentanedione (1.82 
mol, 190 mL) was slowly added over a 1-hour period. After the addition was complete, 
the mixture was stirred at room temperature for 30 minutes. During the addition and the 
room tempterature stirring period, the solution turned from colorless to bright yellow. 
The temperature of the oil bath was raised to 80°C and the reaction was allowed to 
continue with mechanical stirring for another 4 hours. The product precipitates from 
solution during this time. Stirring was halted and the flask was removed from the oil bath. 
After cooling to room temperature, the precipitate was isolated from the reaction mixture 
by vacuum filtration. The precipitate was then washed with cold DI-water. The 
precipitate was then dissolved in dichloromethane (1 L) and washed with water (2 x 500 
mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in 
vacuo. Product 27 was isolated as 97.2 g (79%) as a yellow powder: 1H NMR (500 MHz, 
Chloroform-d) δ 8.06 (s, 2H), 5.96 (s, 2H), 2.49 (s, 6H), 2.22 (s, 6H); 13C NMR (126 
MHz, CDCl3) δ 150.09, 145.92, 142.44, 110.01, 13.94, 13.61. 
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3,6-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine (39). A single-neck 4 L round 
bottom flask was equipped with a stir bar and charged with sodium nitrite (1 mol, 69 g) 
dissolved in 1.5 L DI water. Compound 44 (0.356 mol, 97 g) was dissolved in 1 L 
dichloromethane and added to the flask. Acetic acid (0.854 mol, 49 mL) was added to a 
drop funnel, which was attached to the reaction vessel. The acetic acid was slowly added 
over the course of 10 minutes. The reaction was stirred magnetically for 14 hours, after 
which no further bubbling was witnessed. The reaction mixture was transferred to a 
separatory funnel and  ~300 mL of 5% (w/w) NaCO3 solution was added. The mixture 
was shaken, venting to allow escape of generated CO2. The aqueous and organic layers 
were separated. The organic layer was dried over sodium sulfate, which was subsequently 
removed by vacuum filtration. The organic layer was then concentrated in vacuo. The 
isolated solid was triturated with diethyl ether (~300 mL). Compound 39 was isolated as 
86.2 g (90%) of amorphous red powder: 1H NMR (500 MHz, Chloroform-d) δ 6.17 (s, 
1H), 2.69 (s, 3H), 2.37 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 159.40, 154.56, 143.87, 
111.99, 14.77, 13.96. 
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CAUTION: The dihydrazinyltetrazine product was found to undergo exothermic 
de-composition above 120 °C when analyzed by DSC-TGA under air and ramping 
the temperature at 5o/minute. No decomposition was observed when dihydrazinylte-
trazine was held at 80°C under air for 60 minutes. As a precaution an inert atmos-
phere is highly recommended to prevent any oxidation during the course of the 
reaction. 
3,6-Dihydrazineyl-1,2,4,5-tetrazine (40). In a 1 L round bottom flask, bis-
dimethylpyrazolyl-1,2,4,5-tetrazine (0.318 mol, 86 g) was suspended in acetonitrile (500 
mL). Hydrazine hydrate (0.670, 33 mL) was then added neat via drop funnel over 15 
minutes with magnetic stirring. The reaction vessel was equipped with a reflux condenser 
and the mixture was heated to 85°C of 30 minutes. The reaction vessel was removed 
from heat and allowed to cool to room temperature. The vessel is placed in an ice bath 
and, after the contents have cooled to 0°C, the product is isolated by vacuum filtration 
and dried in vacuo. Dihydrazinyltetrazine was isolated as 38.5 g (99%) of free-flowing 
dark-red amorphous powder: 13C NMR (126 MHz, DMSO) δ 163.36. This compound 
was carried immediately to the next step.  
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3,6-Dichloro-1,2,4,5-tetrazine (1). In a single-neck, 4 L round bottom flask, 
dihydrazinyltetrazine (40) (0.318 mol, 38.5 g) was suspended in acetonitrile (500 mL). 
The flask was equipped with a stir bar and placed in an ice bath on a magnetic stirring 
plate. In a separate beaker, of trichloroisocyanuric acid (0.6517 mol, 151.3 g) is 
transferred to an addition funnel and slowly added to the suspension of 
dihydrazinyltetrazine, being careful to keep the internal temperature of the reaction 
mixture below room temperature. After the addition is complete and the temperature of 
the reaction mixture has stabilized, the flask is removed from the ice bath and the mixture 
is allowed to stir at room temperature for 30 minutes. The reaction mixture was vacuum 
filtered and the white solid precipitate was washed with acetonitrile. The solvent was 
stripped from the filtrate via rotovap (22°C, 70 torr). Dichlorotetrazine can sublimate and 
decomposes under high heat, so careful attention should be paid to keep temperature low 
and watch for the distinctive orange color of the product to collect in the cold trap. 
Removal of the acetonitrile results in the isolation of the crude product as a red-orange 
solid with a strong smell of chlorine. This solid was then dissolved in dichloromethane 
and passed through a celite plug. The resulting filtrate was concentrated in vacuo, again 
being cautious to prevent loss of volatile dichlorotetrazine. This filtration procedure was 
repeated 2 times until only 1 13C carbon signal showed in the NMR spectrum and all 
NN
N N
ClCl
1
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smell of chlorine was gone. Pure dichlorotetrazine was isolated as 47 g (99%) of orange 
crystalline solid: 13C NMR (126 MHz, CDCl3) δ 168.25. 
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